Differential Gene Expression of Murine Blastocyst Stage Embryos and Murine Embryonic Stem Cells by Myer, Sarah E.
DIFFERENTIAL GENE EXPRESSION OF MURINE 
BLASTOCYST STAGE EMBRYOS AND MURINE 
EMBRYONIC STEM CELLS 
 
 
   By 
   SARAH E. MYER 
   Bachelor of Arts in Biology  
   Oral Roberts University 
Tulsa, Oklahoma 
1994 
 
   Masters of Education  
   Oral Roberts University 
Tulsa, Oklahoma 
1995 
 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   DOCTOR OF PHILOSOPHY  
December, 2007  
 ii 
   DIFFERENTIAL GENE EXPRESSION OF MURINE 
BLASTOCYST STAGE EMBRYOS AND MURINE 
EMBRYONIC STEM CELLS 
 
 
 
 
   Dissertation Approved: 
 
 
 
Lee F. Rickords, Ph.D.    
   Dissertation Adviser 
 
Robert W. Allen, Ph.D. 
 
 
Kirby L. Jarolim, Ph.D. 
 
 
Jerry R. Malayer, Ph.D. 
 
    
A. Gordon Emslie, Ph.D. 
   Dean of the Graduate College 
 iii 
ACKNOWLEDGEMENTS 
 
 
In the completion of a doctorate degree, there are invariable many people and 
organizations who deserve special thanks for their support and assistance.  Thank you to 
Dr. Lee Rickords for the opportunity to work within your laboratory, for the willingness 
to work with a non-traditional research student, and for assistance over numerous years of 
graduate study.  Thank you to my graduate committee, Dr. Rob Allen, Dr. Kirby Jarolim, 
and Dr. Jerry Malayer, for your assistance thoughout the research process and your 
thoughtful input into our study.  Thank you to Dr. Ute Hochgeschwender at the 
Oklahoma Medical Research Foundation (OMRF) for the generous donation of the stem 
cell and feeder cell samples not only once, but twice.  
Several individuals deserve special thanks for invaluable research support.  I am 
so thankful to Crystal Shults for her willingness to answer my numerous lab questions, 
for sharing her research wisdom, and for numerous years of laughters, tears, and 
friendship!  Diana Spencer, you have been a special friend as we have together learned 
research methods, as you got me started in real time PCR, and as we experienced the 
frustrations of lab closures.  Thank you.  I am also thankful to Tami Ross Sartashtour for 
her assistance in lab protocols and use of equipment in Dr. Blewett’s lab. 
Numerous additional faculty and staff members have my sincere gratitude for 
assistance throughout the years.  Thank you Dr. David John and Dr. Stan Conrad for 
research support, especially in the tough time after the lab closed and funds were short.  
 iv 
Thank you to Dr. Earl Blewett, Dr. Greg Sawyer, and Dr. Rashmi Kaul for making your 
research space, equipment, and lab technicians available for the completion of this 
research project.  And an additional thank you to Dr. Blewett and Dr. Jarolim who both 
assisted me in an advisor function when needed over the past several years.  Thank you 
also to the administrative assistants who helped me with numerous issues.  A special 
thank you also belongs to Dr. Julie Marino who assisted me with review and analysis of 
the real time data.  Your assistance and encouragement were very appreciated.   
Throughout my time as a graduate student, I have also taught as an Instructor in 
the Biology Department at Oral Roberts University.  This would not have been possible 
without the numerous supportive and giving individuals there who helped in everyway 
possible.  Thank you for switching class sections with me, for praying for me, for 
encouraging me continually, and for every other means of support! 
My family has been an invaluable part of this process.  Thank you for your 
understanding for all of the late birthday cards, Christmas presents, and phone calls!  
Thank you, mom and dad, for your support and encouragement, for giving me a love of 
learning and for teaching me that I could do anything I set my mind to through Christ.  
And thank you, Ross and Caroline, for your encouragement and all of the times you 
helped with the girls or the house!   
I am also thankful to my two beautiful daughters, Hannah and Maggie.  While at 
28 and 11 months, you are too young to be aware of this momentous degree completion, 
your smiles, joy, and cuddles have been a great source of joy and motivation.  You too 
have had to endure long hours at school while I pushed towards completion and it is with 
great anticipation of the time we will share together that I rejoice about being completed.  
 v 
I love you and hope I will always make you proud. 
Most of all, I have an immense gratitude for my husband, Brian Myer.  For the 
almost 15 years of marriage, I’ve been in school for one degree or another for all but 4 
years and yet your support and encouragement never waiver.  Thank you for believing in 
me, for being willing to endure the sacrifices that this has entailed, and for always being a 
rock of encouragement.  I could not have asked God for a better best friend and husband.  
I look forward to moving on into a new phase of life together with you and the girls. 
Beyond those on this earth, I am also immensely thankful to my Father God for 
leading me though the process (Ps. 35:3-5) and being the rock on whom I stand. 
 
 
 
 
 
 
 
 
 
 
 vi 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION......................................................................................................1 
 
 
II. REVIEW OF LITERATURE………………………………………………………6 
  
 Introduction .............................................................................................................6 
 Stem Cell Early History ..........................................................................................6 
 Stem Cell Types and Sources ................................................................................10 
 Embryonal Carcinoma Cells ...........................................................................11 
 Embryonal Germ Cells ....................................................................................11 
 Embryonic Stem Cells .....................................................................................12 
 Adult Stem Cells .............................................................................................13 
 Other Types of Stem Cells ..............................................................................14 
 General Stem Cell Characteristics .........................................................................15 
 Pluripotency and Self Renewal .......................................................................15 
 Culture Dishes ...........................................................................................15 
 Leukemia Inhibitory Factor .......................................................................16 
 Cell Cycle Alterations ...............................................................................17 
 Transcription Factors ................................................................................18 
 Pluripotency Verification ..........................................................................19 
 Karyotype ........................................................................................................20 
 Telomerase Activity ........................................................................................21 
 Variety of Cell Surface Markers .....................................................................23 
 Potential Stem Cell Applications ..........................................................................24 
 Developmental Understanding.........................................................................24 
 Repair of Damaged Tissue/Organ Transplantation..........................................25 
 Drug Development and Other Applications ....................................................27 
 Current Obstacles ............................................................................................28 
 Comparison of Stem Cells and Blastocysts ..........................................................28 
 Potential Techniques .............................................................................................29 
 Suppression Subtraction Hybridization ................................................................30 
 Subsequent Techniques .........................................................................................33  
 Research Focus ......................................................................................................34 
 
 vii 
Chapter          Page 
 
III. METHODOLOGY……………………………………………………………….37 
 
 Sample Collection .................................................................................................38 
 Blastocysts ......................................................................................................38 
 Trophectoderm ................................................................................................39 
 Stem Cells and Feeder Cells ...........................................................................39 
 RNA Extraction .....................................................................................................39 
Blastocysts and Trophectoderm ......................................................................39 
 Stem Cells and Feeder Cells ...........................................................................40 
 Sample cDNA Synthesis .......................................................................................41 
 Blastocysts and Trophectoderm ......................................................................41 
Stem Cells and Feeder Cells ...........................................................................44 
 Suppression Subtraction Hybridization ................................................................46 
 Cloning and Sequencing of Subtracted cDNA .....................................................50 
 Confirmation Through PCR ..................................................................................52 
 Quantification with Real Time Polymerase Chain Reaction ................................53 
 Statistical Analysis ................................................................................................55 
 
 
IV. FINDINGS.............................................................................................................59 
 
 Sample cDNA Synthesis .......................................................................................59 
 Blastocysts and Trophectoderm ......................................................................59 
 Stem Cells and Feeder Cells ...........................................................................60 
 Suppression Subtraction Hybridization ................................................................60 
 Cloning and Sequencing of Subtracted cDNA .....................................................62 
 Confirmation Through PCR ..................................................................................62 
 Quantification with Real Time Polymerase Chain Reaction ................................63 
 Statistical Analysis ................................................................................................64 
 
 
V.  CONCLUSION......................................................................................................92 
 
 Peroxiredoxin 1 .....................................................................................................93 
  Peroxiredoxin 1 Overview ...............................................................................93 
  Peroxiredoxin 1 Cellular Implications .............................................................94 
  Peroxiredoxin 1 Research Significance ...........................................................97 
 Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein..98 
  Ywhaz Overview .............................................................................................98 
  Ywhaz Cellular Implications .........................................................................101 
  Ywhaz Research Significance........................................................................105 
 Voltage-dependent Anion Channel 3 ..................................................................106 
  Vdacs3 Overview...........................................................................................106 
  Vdacs3 Cellular Implications.........................................................................110 
 viii 
Chapter          Page 
 
 
  Vdacs3 Research Significance.......................................................................113 
 General Discussion and Conclusion ....................................................................114 
 
 
REFERENCES ..........................................................................................................125 
 
APPENDIX................................................................................................................137 
  
 Appendix A—Alternative Gene Names ..............................................................138 
 
 Appendix B—Known Ywhaz Target Proteins ....................................................139 
 
 ix
LIST OF TABLES 
 
 
 
Table           Page 
 
 
Chapter III 
 
3.1  Primer Sequences Used in Confirmation PCR Reactions………..………………57 
 
3.2  Primer Sequences Used in Real Time PCR Reactions………………………......58 
 
 
Chapter IV 
 
4.1  GenBank Identities of Sequenced Clones……………………………….…….....76 
 
4.2  Real Time PCR Fold Difference Calculations………………………...………....86 
 
4.3  Levene's Test of Homogeneity of Variance for Quantitative PCR ∆CT Values....90 
 
4.4  ANOVA for Quantitative PCR ∆CT Values.  Comparison of the ∆CT values 
  for each sample within each gene analysis to look for statistical  
  differences.  ANOVA confirmed there were differences in the relative  
  expression levels for all three genes between the 4 samples…………….. ….….90 
 
4.5  Tukey’s HSD for Quantitative PCR ∆CT Values…………….……………..……91 
 
 
Chapter V 
5.1 Cell cycle regulators affected by 14-3-3 binding.  Adapted from Hermeking   
and Benzinger…………………………………………………………………..121 
 
5.2 Cellular localization of Vdac.  Adapted from Reyman, et. al and Shoshan- 
Barmatz and Israelson………………………………………………………......122 
 
5.3 Modifiers of Vdac channel activity.  Adapted from Shoshan-Barmatz  
and Israelson…………………………………………………………………....124 
 x
LIST OF FIGURES 
 
 
 
Figure           Page 
 
 
Chapter II 
 
2.1 Suppression Subtraction Hybridization Differential Gene Amplification ………35 
 
2.2 Suppression Subtraction Hybridization cDNA Production……………..…….....36 
 
 
Chapter IV 
 
4.1 PCR Optimization of Blastocyst Sample.  Aliquots were pulled from a PCR 
reaction of a blastocyst sample, every three cycles from cycle 15 through  
cycle 33 (Lanes 2-8) and analyzed by agarose gel electrophoresis.  The optimum 
number of cycles was determined to as one cycle less than the number required  
to reach plateau amplification.  The optimum number of cycles was determined  
to be 23.  Lane 1 has a 1 KB+ ladder ………………………………………..…..67 
 
4.2 Ligation Efficiency PCR for Blastocyst vs. Blastocyst.  For each sample  
tested by SSH, a ligation efficiency PCR was done with primers for the  
G3PDH gene producing a 500 bp amplicon and an approximately 1.2 kb  
adaptor region amplicon.  This gel shows the bands after 25 cycles as per  
the kit protocol but due to the faint appearance, the PCR was extended for  
another 7 cycles and analyzed by gel electrophoresis a second time which 
showed the bands with greater intensity but also some non-specific  
smearing due to over-amplification. The product visible on the graph verifies  
that sufficient adaptor ligation has occurred for the experiment to continue  
with adequate subtraction efficiency.…………………….……………………...68 
 
4.3 Subtraction Efficiency PCR for Blastocyst vs. Blastocyst.  For each SSH 
comparison, a final control PCR amplified the G3PDH gene in both the  
subtracted and the control unsubtracted sample.  In each PCR, samples  
were pulled at cycles 18, 25, 28, and 33 for analysis by agarose gel 
electrophoresis.  The left side of the gel shows the samples for the subtracted 
followed by the unsubtracted samples for the first blastocyst sample and the  
right side has the same layout for the second blastocyst sample. The four lanes 
 xi
Figure           Page 
 
 
of ladder are all 1 KB+ ladder.  For the first blastocyst sample, the first faint 
product band appears after 25 cycles in the subtracted product, but for the 
unsubtracted control, a significant band is apparent after 18 cycles.  For the 
second blastocyst sample (right), the first faint band appears after 28  
cycles for the subtracted sample but once again has a dark band in the 
unsubtracted control after 18 cycles.  These results confirm that the gene  
levels were indeed decreased in the subtracted products through SSH. ……...…69 
 
4.4 Blastocyst vs. Blastocyst Secondary Subtraction PCR Product.  For each  
pair of comparisons, the amplified subtracted product from the secondary  
PCR reaction and the control unsubtracted product were analyzed by  
agarose gel electrophoresis.  The lanes are as follows: 1 – 1 KB+ ladder,  
2 – subtracted blastocyst sample 1, 3- control unsubtracted blastocyst  
sample 1, 4 – subtracted blastocyst sample 2, 5 – control unsubtracted  
blastocyst sample 2, 6 – control subtracted human skeletal muscle sample,  
7 – control unsubtracted human skeletal muscle sample, and 8 – kit  
control subtracted product.  From the subtracted lanes, a single discrete  
band is visible as compared to the general product smearing seen in the 
unsubtracted lanes.………………………………………………………….……70 
 
4.5 Trophectoderm vs. Blastocyst Secondary Subtraction PCR Product.  For  
each pair of comparisons, the amplified subtracted product from the  
secondary PCR reaction and the control unsubtracted product were  
analyzed by agarose gel electrophoresis.  The lanes are as follows: 1 –  
1 KB+ ladder, 2 – subtracted trophectoderm sample, 3- control  
unsubtracted trophectoderm sample, 4 – subtracted blastocyst sample,  
5 – control unsubtracted blastocyst sample, 6 – control subtracted  
human skeletal muscle sample, 7 – control unsubtracted human skeletal  
muscle sample, 8 – kit control subtracted product, and 9 – 1 KB+ ladder.   
Both the forward and reverse subtraction samples show a general decrease  
of product in comparison to the unsubtracted product, however they still  
show a general smearing of numerous products rather than a limited  
number of discrete product bands.…………………………………………….…71 
 
4.6 129SvEv Stem Cell vs. Blastocyst Secondary Subtraction PCR Product.  
For each pair of comparisons, the amplified subtracted product from the 
secondary PCR reaction and the control unsubtracted product were analyzed  
by agarose gel electrophoresis.  The lanes are as follows: 1 – 1 KB+ ladder,  
2 – subtracted blastocyst sample, 3- control unsubtracted blastocyst sample, 
4 – subtracted stem cells sample, 5 – control unsubtracted stem cell sample,  
6 – control subtracted human placenta sample, 7 – control unsubtracted  
human placenta sample, 8 – control subtracted human skeletal muscle  
sample, and 9 – control unsubtracted human skeletal muscle sample.  Both  
 xii
Figure           Page 
 
 
the forward and reverse subtraction samples show a general decrease in  
number of transcript products in comparison to the unsubtracted product;  
however the stem cell sample showed a substantial decrease of product. ……..72 
 
4.7 129SvEv Stem Cell vs. Fibroblast Feeder Cells Secondary Subtraction PCR 
Product. For each pair of comparisons, the amplified subtracted product  
from the secondary PCR reaction and the control unsubtracted product were 
analyzed by agarose gel electrophoresis.  The lanes are as follows: 1 –  
1 KB+ ladder, 2 – subtracted stem cells sample, 3 – control unsubtracted  
stem cell sample, 4 – subtracted fibroblast sample, 5- control unsubtracted 
fibroblast sample, 6 – control subtracted human skeletal muscle sample, 7 – 
control unsubtracted human skeletal muscle sample, and 8 – kit control  
subtracted product.  All of the subtracted samples showed a visible decrease  
in product. ……………………………………………………………………….73 
 
4.8 Confirmation PCR of Clone 129-1-C1.  DNA sequences identified as 
differentially expressed through Suppression Subtraction Hybridization and 
isolated for cloning were visually confirmed as differentially expressed  
through PCR in the original samples used for comparison.  The lanes are as 
follows: 1 – 1 KB+ ladder, 2 – 129SvEv Stem Cells, 3 – Fibroblast Feeder  
Cells, 4 – C57BL/6 Stem Cells, and 5 – Negative Control.  An increase in  
product is visible in both stem cell samples as in comparison to the fibroblast 
sample, confirming the results of the SSH.………………………………………74 
 
4.9 Confirmation PCR of Clone B5B-C12.  DNA sequences identified as 
differentially expressed through Suppression Subtraction Hybridization and 
isolated for cloning were visually confirmed as differentially expressed  
through PCR in the original samples.  The lanes are as follows: 1 – 1 KB+  
ladder, 2 – Blank, 3 – 129 SvEv Stem Cells, 4 – Blastocyst, 5 – C57BL/6  
Stem Cells, and 6 – Negative Control.  The stem cell samples show a  
greater yield of product than the blastocyst sample, however a number of  
non-specific bands are also visible in the 129SvEv stem cell sample  
indicating a need to optimize the PCR reaction.…………………………………75 
 
4.10 Real Time PCR Amplification Graph for Ribosomal 18s, Run 1.  The graph 
demonstrates the amount of replicated r18s product with each amplification  
cycle in each of the three samples, murine blastocyst, 129SvEv murine  
embryonic stem cells, and C57Bl/6 murine embryonic stem cells, as determined 
by DyNAmo HS SYBR Green fluorescence.  Each sample was tested twice in 
each run.  Each run was repeated a second time for a total of four data sets for 
each gene in each sample.  The second amplification graph for this gene is 
comparable to this graph and is not shown………………………………………78 
 
 xiii 
Figure           Page 
 
 
4.11 Real Time PCR Amplification Graph for Prdx1, Run 1.  The graph  
demonstrates the amount of replicated Prdx1 product with each amplification 
cycle in each of the three samples, murine blastocyst, 129SvEv murine  
embryonic stem cells, and C57Bl/6 murine embryonic stem cells, as  
determined by DyNAmo HS SYBR Green fluorescence.  Each sample was  
tested twice in each run.  Each run was repeated a second time for a total of  
four data sets for each gene in each sample.  The second amplification graph  
for this gene is comparable to this graph and is not shown……………………79 
 
4.12 Real Time PCR Amplification Graph for Ywhaz, Run 1.  The graph  
demonstrates the amount of replicated Ywhaz product with each amplification 
cycle in each of the three samples, murine blastocyst, 129SvEv murine  
embryonic stem cells, and C57Bl/6 murine embryonic stem cells, as  
determined by DyNAmo HS SYBR Green fluorescence.  Each sample was  
tested twice in each run.  Each run was repeated a second time for a total of  
four data sets for each gene in each sample.  The second amplification graph  
for this gene is comparable to this graph and is not shown……………………80 
 
4.13 Real Time PCR Amplification Graph for Vdac3, Run 1.  The graph  
demonstrates the amount of replicated Vdac3 product with each amplification 
cycle in each of the three samples, murine blastocyst, 129SvEv murine  
embryonic stem cells, and C57Bl/6 murine embryonic stem cells, as  
determined by DyNAmo HS SYBR Green fluorescence.  Each sample was  
tested twice in each run.  Each run was repeated a second time for a total of  
four data sets for each gene in each sample.  The second amplification graph  
for this gene is comparable to this graph and is not shown……………………81 
 
4.14 Melting Curve Analysis for Ribosomal 18s Amplification, Run 1.  A melting 
curve analysis was done for each real time PCR run from 50oC to 90oC.  The 
graph is of the rate of change of relative fluorescence with time and therefore 
peaks at the melting temperature of the product.  This graph demonstrates a 
uniform peaking at the r18s melting point (84.4 oC) for all samples and  
confirms that fluorescence reading within those wells were only due to the 
presence of the desired amplicon and not primer dimers or random priming 
products.  The melting curve for the second run is comparable to this graph  
and therefore is not shown……………………………………………………….82 
 
4.15 Melting Curve Analysis for Prdx1 Amplification, Run 1.  A melting curve 
analysis was done for each real time PCR run from 50oC to 90oC.  The graph is  
of the rate of change of relative fluorescence with time and therefore peaks at the 
melting temperature of the product.  This graph demonstrates a uniform peaking 
at the Prdx1 melting point (78.8 oC) for all samples and confirms that 
fluorescence reading within those wells were only due to the presence of the  
 xiv
Figure           Page 
 
 
desired amplicon and not primer dimers or random priming products.  The 
melting curve for the second run is comparable to this graph and therefore is  
not shown………………………………………………………………………...83 
 
4.16 Melting Curve Analysis for Ywhaz Amplification, Run 1.  A melting curve 
analysis was done for each real time PCR run from 50oC to 90oC.  The graph is  
of the rate of change of relative fluorescence with time and therefore peaks at the 
melting temperature of the product.  This graph demonstrates a uniform peaking 
at the Ywhaz melting point (79.6 oC) for all samples and confirms that 
fluorescence reading within those wells were only due to the presence of the 
desired amplicon and not primer dimers or random priming products.  The 
melting curve for the second run is comparable to this graph and therefore is  
not shown………………………………………………………………………...84 
 
4.17 Melting Curve Analysis for Vdac3 Amplification, Run 1.  A melting curve 
analysis was done for each real time PCR run from 50oC to 90oC.  The graph is  
of the rate of change of relative fluorescence with time and therefore peaks at the 
melting temperature of the product.  This graph demonstrates a uniform peaking 
at the Vdac3 melting point (81.6 oC) for all samples and confirms that 
fluorescence reading within those wells were only due to the presence of the 
desired amplicon and not primer dimers or random priming products.  The 
melting curve for the second run is comparable to this graph and therefore is  
not shown………………………………………………………………………...85 
 
4.18 Fold Differences in Prdx1 Gene Expression Levels Based on Real Time PCR.  
Notations a-c indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For a, p = 0.034, for b,  
p = 0.014, and for c, p = 0.000……………………………………………….…87 
 
4.19 Fold Differences in Ywhaz Gene Expression Levels Based on Real Time PCR.  
Notations a-d indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For a, p = 0.045, for b,  
p = 0.000, for c, p = 0.000, and for d, p = 0.000………………………………..88 
 
4.20 Fold Differences in Vdacs3 Gene Expression Levels Based on Real Time PCR.  
Notations a-d indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For all four comparisons,   
p = 0.000…………………………………………………………………………89 
 
 
Chapter V 
 
5.1 Reduction of Hydrogen Peroxide by Peroxiredoxin……………………………117   
 xv
Figure           Page 
 
 
5.2  14-3-3 Dimeric Structure.  The nine alpha helices are shown as cylinders and 
notated as αA – αI………………………………………………………………118 
 
5.3      14-3-3 Apoptosis Regulation. 14-3-3 proteins, indicated by the copper  
colored dimeric loops, sequester proapoptotic proteins in the cytoplasm as a  
result of cellular survival signals.  JNK phosphorylation of 14-3-3 dimers at  
Ser 184 or the formation of 14-3-3 monomers by the phosphorylation at S58  
by SDK/PKA in response to cellular damage or stress signals causes the  
release of these proapoptotic proteins and their subsequent migration to the 
mitochondria or nucleus………………………………………………………...119 
 
5.4 Summary of 14-3-3 protein interactions during the cell cycle.  Taken from 
Hermeking and Benzinger……………………………………………………...120 
 
5.5 Model of VDAC in the Mitochondrial Membrane.........................................….123 
 
 
 xvi
ABBREVIATIONS 
AFS     Amniotic fluid-derived stem cells 
AIF     Apoptosis inducing factor 
ALBP     Adipocyte lipid-binding protein 
ANOVA    Analysis of variance 
ANT     Adenine nucleotide translocase/translocator 
ASK1     Apoptosis signal regulated kinase 1 
BAD     Bcl2-3 antagonist causing cell death protein or 
      BCL-2/XL associated death promoter 
Bcl2     B-cell CLL/lymphoma 2 protein 
bFGF     Basic fibroblast growth factor 
Bim     BCL-2 interacting mediator of cell death 
BLAST    Basic local alignment and search tool 
BP     Base pair 
BSA     Bovine serum albumin 
BWW     Biggers, Whitten, Whittingham media 
c-Abl      Abelson leukemia oncogene 
CBP      Cruciform binding protein 
Cdc2      Cell division cycle 2; also known as Cdk1 
Cdk     Cyclin-dependent kinase 
cDNA     Complementary deoxyribonucleic acid 
CDS primer    SMART cDNA synthesis primer 
CFTR     Cystic fibrosis transmembrane conductance  
regulator 
Chk1     Checkpoint 1 kinase 
CKIα      Casein kinase Iα 
c-Myc      Myelocytomatosis oncogene 
Cys-SOH     Cysteine sulfenic acid 
DIA     Differentiation-inhibiting factor 
DRF     Differentiation-retarding factor 
EC cells    Embryonal carcinoma cells 
EDTA     Ethylenediaminetetraacetic acid 
EG cells    Embryonic germ cells 
ERK     Extracellular signal-regulated kinase 
ES cells    Embryonic stem cells 
EST     Expressed sequence tag 
FACS     Fluorescence-activated cell sorting 
FAT     Fatty acid transporter 
FBS     Fetal bovine serum
 xvii
FGF2     Fibroblast growth factor 2 
Fkhr     Forkhead in rhabdomyosarcoma transcription factor 
Foxo     Forkhead box, subgroup O protein 
G0     Resting phase of the cell cycle 
G1     Gap 1 phase of the cell cycle 
G3PDH     Glyceraldehyde-3-phosphate dehydrogenase 
GAPDH    Glyceraldehyde-3-phosphate dehydrogenase 
GDNF     Glial cell line-derived neurotrophic factor 
gp130     Glycoprotein 130 
hCG     Human chorionic gonadotrophin 
hES     Human embryonic stem cells 
HNF-4     Hepatocyte nuclear factor-4 
H2O2     Hydrogen peroxide 
ICM     Inner cell mass 
IP     Intellectual property 
IU     International units 
IVF     In vitro fertilization  
JNK     c-Jun N-terminal kinase 
kDa     Kilodalton 
KB     Kilobase pairs 
LIF     Leukemia inhibitory factor 
MEF     Murine embryonic fibroblast 
MEK     Mitogen activated protein kinase kinase 
mRNA     Messenger ribonucleic acid 
MST2     Mammalian sterile 20-like kinase 2 
MPT     Mitochondrial membrane permeability transition 
NCBI     National Center for Biotechnology Information 
NIA     National Institute on Aging 
Nrf2     Nuclear factor (erythroid-derived-2)-related factor 
Oct-4     Octamer-binding transcription factor 4 
OMM     Outer mitochondrial membrane 
ORCC     Outwardly rectifying chloride channel 
Pax-6     Paired box gene 6 
PBS     Phosphate buffered saline 
PCR     Polymerase chain reaction 
PGC     Primordial germ cells 
Pka     Protein kinase A 
PMSG     Pregnant mare serum gonadotrophin 
POU     Pit-Oct-Unc  - transcription factor family 
Prdx1     Peroxiredoxin 1 
Prdxs     Peroxiredoxin gene family 
PTP     Permeability transition pore 
PTP     Protein tyrosine phosphatases 
ROS     Reactive oxygen species 
RT     Reverse transcriptase 
S phase    Synthesis phase of the cell cycle 
 xviii 
Sdk1     Sphingosine-dependent kinase 
SNP     Single nucleotide polymorphism 
S.O.C. medium    Super Optimal Catabolite Repression Broth 
SR     Sarcoplasmic reticulum 
SSEA     Stage-specific embryonic antigen 
SSH     Suppression subtraction hybridization 
STAT-3    Transcription factor 3 
TRX     Thioredoxin 
Vdac     Voltage-dependent anion channel protein family 
Vdac3     Voltage-dependent anion channel 3 
WARF     Wisconsin Alumni Research Foundation 
Yap     Yes-associated transcriptional activator protein 
Ywhaz     Tyrosine 3-monooxygenase/tryptophan -  
5-monooxygenase activation protein, zeta 
peptide or 14-3-3 zeta 
 1 
CHAPTER I 
 
 
INTRODUCTION 
 
 
 While there have been many notable research discoveries throughout history, few 
have gained the level of attention of stem cells.  In the time since the first isolation of 
mouse stem cell cultures in 1981, human and mouse stem cell research has grown 
exponentially and has captured the interest of the public with promises of potential cures 
to medical conditions such as paralysis and Alzheimer’s disease.   
A review of stem cell research demonstrates the complexity of the subject as 
multiple types of stem cells have been described with varying characteristics and research 
potential.  Stem cell types include embryonic stem cells, adult stem cells, embryonic 
germ cells, embryonic carcinoma stem cells, umbilical cord stem cells, and amniotic 
fluid-derived stem cells.  In general, stem cells are undifferentiated cells that have the 
ability for self-renewal and the ability to form one or more specialized cell types.  While 
multiple types of stem cells have been studied, the embryonic stem cell is believed to 
have the greatest potential for research and medical applications due mostly to its ability 
to form numerous cell types.  Research with human embryonic stem cells has faced 
limitations however due to ethical concerns over the methods used for their generation. 
While a reflection on the stem cell literature shows a great amount of work done 
to characterize the various types of stem cells and their potential, much less work has 
 2 
been done to characterize the molecular transition that occurs in the formation of 
embryonic stem cells from blastocyst stage embryos.  One project analyzed gene 
expression levels as determined by expressed sequence tag (EST) frequencies common to 
various cellular and developmental stages (pre-implantation embryos, pluripotent stem 
cells, adult stem cells, etc.), however, it failed to directly measure gene expression levels 
or to characterize the blastocyst to stem cell transition [1].  Having a greater 
understanding of this molecular transition will provide a more complete picture of 
general development processes, of embryonic stem cell characteristics, and of the 
requirements for embryonic stem cell development.  Long term, having a greater 
understanding of this process may lead to the ability to produce better alternative stem 
cell sources. 
Several techniques are available for characterizing variations in gene expression 
including microarrays and Northern Blots, however, with limited starting material and a 
lack of information about which genes would be significantly altered, the best technique 
for this project was suppression subtraction hybridization (SSH).  SSH allows the 
researcher to compare small amounts of transcripts from two sources and the process 
combines normalization and subtraction.  mRNA is used to produce cDNA for both 
sources which are subsequently hybridized in order to isolate unique unhybridized cDNA 
samples for analysis. 
After unique transcripts are amplified from both sources, the transcripts are 
cloned, sequenced, and identified through databank comparison.  Differential expression 
of genes identified through SSH should be confirmed and ultimately the differential 
expression can be quantified through real time polymerase chain reaction (PCR).  
 3 
In this study, four SSH comparisons were performed using CD1 mice and 
129SvEv murine embryonic stem cells (ESC) - blastocyst vs. blastocyst, trophectoderm 
vs. blastocyst, 129 SvEv ESC vs. fibroblast feeder cells, and blastocyst vs. 129 SvEv 
ESC – with the first three comparisons serving as control comparisons and the last 
comparison being the primary comparison of interest.  From these four comparisons, 
sequences were obtained for 33 clones of uniquely expressed transcripts and identified 
through the National Center for Biotechnology Information (NCBI) Basic Local 
Alignment and Search Tool (BLAST).  From the 33 unique clones identified through 
SSH, 10 had strong homologies to ribosomal subunits while 23 had either gene specific 
homologies or else were unknown.  
The second objective was to quantify the rate of expression of three selected 
transcripts through real time PCR in blastocysts, 129SvEv ESC, C57BL/6 ESC, and 
fibroblast feeder cells.  A second strain of murine stem cells (C57BL/6) was included to 
confirm that differences were stage specific (for example, stem cells or blastocyst) 
variations and were not related to species specific variations.  The three genes, 
peroxiredoxin 1 (Prdx 1), tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein (Ywhaz), and voltage-dependent anion channel 3 (Vdacs3), were all 
found to be uniquely expressed in the blastocyst versus embryonic stem cell comparison, 
the main comparison of interest. 
The real time PCR results were as follows.  For Prdx1, fibroblast feeder cells had 
the lowest expression level, blastocysts had a 4.81 fold increase, 129SvEv ESC had a 
7.51 fold increase, and the C57BL/6 ESC showed a 27.28 fold increase.  Expression 
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levels were significantly different between the blastocyst and C57BL/6 samples as well 
as the fibroblast feeder cells and both ESC samples based on ∆CT statistical analysis.   
For Ywhaz, the fibroblast feeder sample showed the lowest expression level, 
blastocysts had a 7.65 fold increase, 129SvEv ESC showed a 6.49 fold increase, and 
C57BL/6 ESC showed a 16.56 fold difference.  The two ESC values were significantly 
different as was the fibroblast feeder cell value from all other samples.   
For Vdacs3, the blastocyst sample had the lowest level of expression, fibroblast 
feeder cells had a 2.16 fold difference, 129SvEv ESC had a 68.07 fold difference, and 
C57BL/6 ESC had a 161.04 fold difference.  Statistically, the blastocyst sample was 
different from both of the ESC samples and the fibroblast sample from either ESC 
sample.   
A review of research literature for the three genes specifically studied through real 
time PCR, Prdx1, Ywhaz, and Vdac3, suggests important roles in promoting cell survival 
and continued cell division.  Alterations of expression levels of all three genes have been 
found in cancer lines which have similar characteristics of continued cell division without 
normal occurrence of differentiation.  In addition, all three genes have been suggested as 
direct or downstream targets of Oct4, an essential gene known for its role in maintaining 
stem cell pluripotency [2].  While much research remains to fully understand the actions 
of each of these genes within the cell, especially in distinguishing differences in gene 
isoform actions within the cell, the overall focus on allowing continued stem cell growth 
is clear. 
This current work identifies a small sample of the potential genes involved in the 
transition from blastocyst stage embryo to embryonic stem cell line and offers a valuable 
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first step in understanding the molecular alterations that occur during this essential time 
period.  Peroxiredoxin 1 and Voltage dependent anion channel 3 both demonstrated 
significant upregulation in the comparison between blastocyst stage embryos and ESC 
and function to enhance cell survival and continued cell reproduction.  The significant 
difference of expression combined with the complex involvement of these three genes in 
cellular regulation open the door to better understanding the blastocyst to ESC transition.  
Hopefully future research will continue to expand our understanding of this transitional 
period in order to identify key markers of stem cell development in embryonic sources 
with potential applications in the development of additional stem cell sources. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
 
Introduction 
 
 
 The general term “stem cell” commonly refers to undifferentiated cells that have 
the ability for self-renewal and the ability to form one or more specialized cell types.  
Stem cells that are able to produce a range of differentiated cells that would normally 
arise from the three germ layers of a developing embryo are called pluripotent.  The 
broadest term, totipotent, indicating a potential for forming all cell types, is generally 
reserved for the fertilized egg which forms cells composing all three germ layers plus 
extraembryonic tissue such as the placenta.  Stem cells can also be multipotent, meaning 
they can form several types of differentiated cells, or unipotent, meaning they can form 
only one type of differentiated cell.  Pluripotent stem cells provide the greatest medical 
research potential due to their diverse developmental potential. 
  
Stem Cell Early History 
 
 
 Much of the early research with stem cells was done using mouse models as is 
evidenced by a review of stem cell research advances.  In fact, long term cultures of 
mammalian embryonic stem cells have only been achieved so far in mice, monkeys, and 
humans [3].  The first mouse stem cell lines were first isolated in the 1960’s and 1980’s 
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with human stem cell line isolation not to follow until the late 1990’s.  Murine stem cell 
research is important since it has provided much of the basic knowledge about stem cells 
while much of the current research focuses on therapeutic applications with human stem 
cells. 
 Experimentation with pluripotent stem cells began with the research on 
teratocarcinomas in the mouse by Leroy Stevens in the late 1960’s.  Culture of cells from 
these tumors led to the isolation of the first embryonic carcinoma (EC) cells, which were 
later shown to be able to produce cells characteristic of all three germ layers [4, 5]. 
 By the mid-1970’s, the potential of using EC cells for therapeutic purposes was 
acknowledged, but with hesitation due to their aneuploidy, common among cancer cell 
lines [5].  Nevertheless, the possibilities prompted additional research in the field of 
murine and human stem cell biology.  Researchers already knew that teratocarcinomas 
could be developed by placing post-implantion embryos into ectopic sites.  This led to the 
idea that perhaps stem cells could be isolated directly from the blastocysts without going 
through the process of teratocarcinoma development [6]. 
 This concept of isolating stem cells directly from blastocysts led researchers 
Martin J. Evans and Matt H. Kaufman of Cambridge and Gail Martin of the University of 
California to independently develop the first mouse embryonic stem (ES or ESC) cell 
lines in 1981 [5, 7, 8]  Evans and Kaufmann isolated the ES cell line by directly culturing 
blastocyst stage murine embryos from 129SvEv mice.  Blastocysts were forced to enter 
diapause via a maternal ovariectomy between fertilization and blastocyst collection in 
order to increase cell numbers without allowing development past the formation of the 
primary endoderm.  The blastocysts were collected and placed in tissue culture media for 
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several days.  After “egg cylinder-like structures” had developed from the inner cell 
mass, these structures were removed and placed in culture with a mitomycin C-
inactivated STO fibroblast feeder layer.  Colonies of cells resembling EC cells were 
further isolated and grown for more than 30 passages.  The cell lines were found to have 
a normal karyotype, to be able to produce embryoid bodies when passaged without feeder 
layers, and to be able to produce teratocarcinomas when injected subcutaneously [7].  
 The research by Gail Martin used slightly different techniques to achieve a stem 
cell line directly from early stage embryos.  Early blastocysts were flushed from plugged 
superovulated ICR females that had been bred with SWR/J males.  The cells were 
cultured until late blastocysts were obtained.  Immunosurgery was used to isolate inner 
cell mass (ICM) which were grown on a feeder layer of mitomycin C-treated STO 
fibroblast in media that had been previously conditioned by growth of a PSA-1 
embryonal carcinoma cell line.  Stem cells formed from the ICM and after five passages, 
conditioned media was no longer required for proliferation.  The stem cell line 
demonstrated the ability to form teratocarcinomas in vivo as well as the ability to 
differentiate into a variety of tissue types in vitro [8]. 
 The first human stem cells were isolated in 1994 from embryos donated by 
patients undergoing in vitro fertilization (IVF) treatment.  Twenty-one fertilized eggs 
were grown to the blastocyst stage, “healthy” ICM were isolated and cultured from 19 
blastocysts, and 17 produced growths with “stem cell-like morphology” for up to two 
passages [9]. 
Subsequently, a human pluripotent stem cell line was first established in 1998.  
James A. Thomson from the University of Wisconsin also cultured donated IVF embryos 
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in order to obtained human embryonic stem (hES) cells.  Five stem cell lines were 
produced, three that had XY karyotypes and two that had XX.  In addition to having 
normal karyotypes, the cells had high telomerase activity, were able to be cultured for 
several months, and were shown to maintain pluripotency [10].   
 At about the same time, researchers at John Hopkins University led by John 
Gearhart, isolated the first human embryonic germ (EG) cell line from the primordial 
germ cells of aborted fetuses (5-9 weeks old).  The cultures were karyotypically normal 
(both XX and XY) and were able to produce embryoid bodies containing differentiated 
tissue belonging to all three germ layers.  This provided a second source of human 
pluripotent stem cells for research [11].  
Since this early research, a great deal of national and international research has 
focused on stem cell characteristics, growth requirements, and differentiation potential 
for both mouse and human stem cells.  While many believe embryonic stem cells have 
the greatest scientific and medical applications, several factors have limited human 
embryonic stem cell research within the United States.   In 2001, due to ethical concerns 
about the derivation of human embryonic stem cells from early embryos, President Bush 
limited the use of federal research funds to those stem cell lines already created from 
surplus IVF embryos.  At the present, there are 78 eligible human embryonic cell lines 
listed on the National Institute of Health’s Human Embryonic Stem Cell Registry 
(http://stemcells.nih.gov/research/registry/defaultpage.asp), however not all of these lines 
have proven to be viable for research and only 21 lines are currently listed as available 
for use [12].   
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In addition, patent issues have arisen.  The Wisconsin Alumni Research 
Foundation (WARF) at the University of Wisconsin, Madison, site of James Thomason’s 
human ESC line discovery, holds two intellectual property (IP) patents on human 
embryonic stem cells, the only such patent in the world.  (They also hold 5 of the 21 
available human ESC lines on the NIH registry.)  Within the two patents, claims include 
methods of primate and human ESC derivation in addition to the actual stem cells as well 
as all derivatives of human embryonic stem cells.  WARF has required licenses for both 
academic and commercial institutions and has charged per cell line, per investigator 
rather than the customary one-charge per institution.  While some institutions have 
chosen to infringe on the IP patent rather than pay the numerous fees, others have 
challenged the patent in court, and some have chosen to move their research outside of 
the United States [13]. 
 
Stem Cell Types and Source 
Despite the common usage of the term “stem cell”, much confusion still remains 
about the various stem cell types and sources.  Stem cells are often divided based on the 
source – adult, fetal, or embryonic tissue.  The two types of stem cells isolated from fetal 
and embryonic tissue are both pluripotent.  Fetal derived stem cells are called embryonic 
germ (EG or EGC) cells while stem cells derived from the embryonic blastocysts are 
called embryonic stem (ES or ESC) cells. 
 Adult stem cells are isolated from adult body tissue and generally function in 
normal body maintenance.  While these cells are valuable in normal body function, most 
are not naturally pluripotent.  The unique pluripotent stem cells derived from adult tissue 
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is the embryonal carcinoma (EC) stem cell line.  Other types of stem cells often discussed 
include umbilical cord stem cells and most recently, amniotic fluid-derived stem cells. 
  
Embryonal Carcinoma Cells 
 Embryonal carcinoma (EC) stem cell lines are isolated from testicular teratomas, 
also called teratocarcinomas.  This type of tumor is composed of a mixture of tissue, not 
characteristic of the testis, but rather a conglomerate of those derived from the three germ 
layers of the developing embryo [14, 15].  A large variety of tissue may be included such 
as cartilage, bone, muscle, and epithelia.  They originate from primordial germ cells 
(PGCs) which during development normally lead to the production of eggs or sperm [4].   
 When these EC cells within the tumor are isolated from the teratocarcinomas and 
cultured in vitro, long term pluripotent cultures of EC stem cells can be produced.  One 
difference in EC cells from other types of stem cells is that they often exhibit 
heteroploidy or abnormal chromosome numbers [4].  This is not surprising considering 
their carcinoma origin and even though EC cells are pluripotent like EG and ES cells, 
their research potential is limited by their chromosomal abnormalities and therefore are 
not utilized or discussed as frequently as the other forms of stem cells. 
 
Embryonal Germ Cells 
 
 
 Like the embryonal carcinoma stem cells, embryonal germ (EG) cells also 
originate from PGCs.  However, while EC cells are obtained from abnormal growth of 
PGCs in adult tissue, EG cells are obtained from developing fetal tissue.  In the 
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developing human embryo, PGCs migrate from the yolk sac to a region of the posterior 
body wall forming the gonadal ridge which will eventually lead to the formation of 
ovaries or testis [16].  If the PGCs are isolated from the gonadal ridge within the fifth to 
tenth week of development and cultured in vitro with feeder layers, colonies of 
pluripotent EG cells are developed [4, 14]. 
 In the mouse, the PGCs are first identifiable around day 8 after which these few 
cells (10-100) migrate to the genital ridge.  During the migration, the cells replicate so 
that by day 13.5, the genital ridge is populated by approximately 25,000 PGCs.  Isolation 
of murine PGCs occurs from about day 11.5 and later [17]. 
 
Embryonic Stem Cells 
 
 
 Both embryonal germ cells and embryonic stem (ES) cells are isolated from the 
early developing embryo; however the embryonal germ cells are isolated at a post-
implantation stage while the embryonal stem cells are isolated from the pre-implantation 
blastocyst stage embryo.  In the mouse, the blastocyst stage embryo is composed of about 
150 cells divided into regions.  The outer layer of cells is called the trophectoderm, an 
inner cluster of cells is called the inner cell mass, and the two are mostly divided by a 
fluid-filled cavity called the blastocoel.  When the blastocyst stage embryos are cultured 
in vitro, some colonies develop that are stem-cell like.  These cells are subcultured on 
feeder layers leading to the formation of ES cell lines [4].  
 When stem cells are referenced in general, often the reference may be to ES cells.  
Currently ES cell lines have only been isolated from three mammalian species – mice, 
humans, and monkeys [3, 4, 14].  (EC and EG cells have only been isolated from mice 
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and humans.)  Research on murine ES cells first became possible about 20 years ago and 
since that time they have been involved in a great deal of research.  Characteristics that 
make them valuable in research include their ability to replicate indefinitely, their normal 
chromosome number, and their pluripotency. 
 
Adult Stem Cells 
 
 
 Adult stem cells in general are considered relatively rare and were not originally 
believed to be distributed throughout the adult human body.  They have, however, been 
found naturally occurring in many body tissues and have now been isolated from tissues 
that originated from all three embryonic germ layers, including the bone marrow, blood, 
brain, cornea, gastrointestinal tract, liver, pancrease, retina, tooth dental pulp, skeletal 
muscles, and skin [14].  A common example is the multipotent hematopoietic stem cells 
which form the erythrocytes and the leukocytes of the blood. 
 Adult stem cells are undifferentiated and function in normal body maintenance to 
replace damaged or dying cells.  The stem cells divide producing both a new stem cell 
and a second cell that develops to become the needed differentiated cell.  However, 
unlike ES cells, most adult stem cells are not naturally pluripotent.   As exceptions, 
murine spermatogonial stem cells and multipotent adult progenitor cells (MAPCs) 
obtained from the culture of human bone marrow have been reported to demonstrate 
pluripotency [18, 19].   
Researchers though have questioned the plasticity or the ability of one type of 
adult stem cell to form a different type of tissue through “genetic reprogramming” via 
altered growth or differentiation conditions and the belief that the developmental 
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potential of adult stem cells is unchangeable has been contradicted by numerous research 
findings [4, 19].  One concern, however, about some of the early experiments was that 
the researchers often used a heterogenous pool of cells rather than demonstrate plasticity 
with a clonal pool of identical stem cells [14].  
 While other types of stem cells are often encompassed with ethical debates about 
their origins, adult stem cells have been proposed by some as an equal alternative.  
Several problems, however, currently exist with the widespread use of adult stem cells 
for research and therapeutic applications such as the limited availability of pluripotent 
adult stem cells as well as the difficulty in locating and isolating the adult stem cells. 
 In addition, while adult stem cells are able to continue to replicate in vivo, 
researchers have had difficulty in maintaining long term cultures in vitro.  Adult stem 
cells have not been shown to replicate indefinitely like ES cells but often undergo 
differentiation in culture instead.  This is problematic since researchers need large 
numbers of stem cells for experimentation and therapeutic procedures but are unable to 
grow them in vitro [4]. 
 
Other Types of Stem Cells 
 There are several other types of stem cells that may be utilized in research.  
Umbilical cord stem cells are multipotent cells taken from the umbilical cord at time of 
birth.  Since they are genetically identical to the child, they hold great research promise 
for patient specific therapy [3].    In addition, isolation of a new type of stem cell from 
human, mouse, and rat amniotic fluid with both embryonic and adult stem cell markers 
was recently published.  These amniotic fluid-derived stem (AFS) cells avoid the ethical 
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debate associated with embryonic stem cells, grow without a feeder layer, and are 
pluripotent, having been induced to form tissue characteristic of each germ layer 
(“adipogenic, osteogenic, myogenic, endothelial, neurogenic, and hepatic”).  In addition 
to isolation from fluids collected via amniocentesis, these cells have also been isolated 
from prenatal chorionic villi and placental biopsies proving they are very accessible.  
Unlike ES cells, the AFS cells also proved to be nontumorigenic when implanted in vivo 
which may prove extremely useful in future therapeutic applications [20, 21]. 
 
General Stem Cell Characteristics 
Much of the stem cell research within the last decade has focused on discovering 
stem cell characteristics.  While each type of stem cell has some unique characteristics, 
there are also some common traits among most types including the ability for self-
renewal in a pluripotent/multipotent state, maintenance of a normal karyotype, telomerase 
activity in maintaining full length telomeres, and expression of characteristic cell surface 
markers. 
 
Pluripotency and Self-Renewal 
Culture Dish 
    One basic characteristic is the ability for in vitro self-renewal in an 
undifferentiated state.  This is a pluripotent/multipotent state for all stem cells other than 
adult stem cells.  While researchers are still determining the factors required for 
maintaining an undifferentiated state, several factors have been discovered.  One basic 
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determinant is the type of culture dish that is used.  Dishes that have an adherent surface 
discourage differentiation while non-adherant surfaces allow embryoid body formation 
and differentiation [4]. 
 
Leukemia Inhibitory Factor 
 
 Secreted factors such as leukemia inhibitory factor (LIF) also play an important 
role in the maintenance of an undifferentiated state.  LIF is a 45 kDa cytokine which has 
also been known as differentiation-inhibiting factor (DIA) and differentiation-retarding 
factor (DRF).  It is normally secreted from numerous cell types including T cells, 
fibroblasts, the liver, and the heart [22].  It’s secretion by the mitotically-inactivated 
murine embryonic fibroblast (MEF) cells upon which stem cells are normally grown is 
essential for the maintenance of the undifferentiated state.  In murine ES cell cultures 
however, addition of LIF can actually replace the need for MEF feeder cells  [4].  In 
addition to LIF, EG cell isolation requires two additional factors, Kit ligand and basic 
fibroblast growth factor (bFGF or FGF2) [4]. 
 While LIF has numerous actions within the body including promoting bone 
resorption, causing a decrease in body fat, and promoting hematopoiesis, LIF promotes 
maintenance of the undifferentiated state and continued division in stem cell cultures 
[22].  LIF works within the stem cells by activating glycoprotein 130 (gp 130) which 
affects the signal transducer and activation of transcription-3 (STAT-3) molecule as well 
as other molecules such as mitogen-activated protein kinase.  The activation of the 
mitogen-activated protein kinase however has been reported to be a counter-balance in 
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that it seems to inhibit the ability for continued self-renewal [4]. 
 In contrast to murine ES cells, while human ES cultures generally do require 
feeder cells (with the exception of the AFS cells), they do not require LIF.  Since the 
feeder cells are also secreting other factors, it has been proposed that perhaps the same 
downstream signaling molecules are being activated [4].  MEF feeder cells are the most 
common, however due to concern about the potential transfer of animal pathogens and in 
attempts to improve stem cell growth and differentiation, numerous other types of feeder 
layers have also been tried including human placenta-derived feeders, human bone 
marrow-derived feeders, and human glioblastoma feeders [3, 23, 24].   
 
Cell Cycle Alterations 
 
 Alterations in the cell cycle also play an important role in the maintenance of 
pluripotency and self-renewal.  Researchers have found that stem cells seem to lack the 
gap 1 (G1) checkpoint in the cell cycle.  External stimuli are not required for replication 
to begin and ES cells spend the majority of their time in the synthesis (S) phase of the cell 
cycle replicating DNA in preparation for cell division [14]. 
 In a normal eukaryotic somatic cell cycle, the G1 phase is preparation for the S 
phase and contains a regulated checkpoint that determines whether the cell enters the S 
phase or a G0 resting phase.  The checkpoint is regulated by a delicate balance of factors 
including cell to cell contact, cell differentiation, and anti-mitogenic factors that all 
promote transition to G0 and mitogens (extracellular growth factors) and nutrients which 
promote continued transition through the restriction checkpoint and into the S phase.  The 
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presence or absence of these various factors influences a cascade of biochemical events 
involving cyclin-dependent kinases that control the transition.  Without this checkpoint in 
somatic cells, uncontrolled cell division can lead to the development of cancer [25].  In 
stem cells, the lack of the checkpoint allows the cells to continue dividing without 
entering a differentiation stage. 
 
Transcription Factors 
 
 In addition to secreted factors, culture dishes, and cell cycle alterations, 
transcription factors also play a large role in the pluripotent self-renewal capacity of stem 
cells.  Certain transcription factors are characteristic of undifferentiated pluripotent stem 
cells in both humans and mice such as Sox2, genesis (also known as FoxD3), germ cell 
nuclear factor, nanog, fibroblast growth factor (Fgf4), undifferentiated embryonic cell 
transcription factor (Utf1), reduced expression (Rex-1), and octamer-binding 
transcription factor 4 (Oct-4; also known as Oct-3 and Oct-3/4) [14, 26].  In fact, many of 
these identified transcription factors have been shown to be directly influenced by Oct-4 
as they work together to prevent cellular differentiation [26]. 
 Oct-4 is a POU-domain transcription factor that is key for the maintenance of an 
undifferentiated state.  Recently Oct-4 has also been renamed as POU domain class 5 
transcription factor 1 (Pou5f1) [2].  Researchers have found that Oct-4 is essential in 
early embryonic development for pluripotency and that embryos lacking Oct-4 fail to 
develop an ICM in a blastocyst stage embryo [27].  When Oct-4 is downregulated in ES 
cells, differentiation begins [4].  Oct-4 was also found to be expressed in over 90% of the 
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AFS stem cells recently described [20] and in numerous types of adult stem cells [28].  In 
contrast however to the majority of research indicating Oct-4 expression as an important 
characteristic of undifferentiated cells (i.e. embryonic and stem cells), one recent study 
found Oct-4 expression in human peripheral blood mononuclear cells bringing to 
question its use as a marker of pluripotency [28].  
 Other transcription factors are characteristic in the differentiation of stem cells.  
For example, Pax6 is expressed as ES cells form neuroepithelium, hepatocyte nuclear 
factor-4 (HNF-4) is expressed as endoderm is formed, and brachyury is expressed as 
mesoderm is formed [14].  The presence of these transcription factors can therefore be 
used to identify cells in the process of differentiation. 
 
Pluripotency Verification 
 
 The pluripotency of ES, EC, and EG cells have been verified by various 
experiments.  When the pluripotent stem cells are injected into the blastocoel of a 
blastocyst stage embryo and implanted into the uterus of a surrogate mouse, a chimeric 
mouse develops which contains a mixture of tissue derived from both the original 
blastocyst and the stem cells.  The ES and EG cells contribute to all cell types, including 
the germ line.  The EC cells, however, failed to contribute to the germline in most 
instances which could be due to their abnormal chromosome numbers [4]. 
 A second similar test involves injection of ES cells into a blastocyst devoid of its 
ICM.  When allowed to develop, the recreated blastocyst successfully develops into a 
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complete embryo [14].  These experiments alone verify the ability of the ES cells to form 
tissue derived from all three germ layers. 
 A third test involved the injection of pluripotent stem cells either under the skin or 
into the kidney of an immunocompromised or genetically identical mouse.  The stem 
cells form a teratoma containing a mixture of differentiated or partially differentiated 
tissue as is in a normal teratoma.  Teratomas formed by hES included tissues such as gut 
epithelia, cartilage, smooth muscle, neural epithelial, and stratified squamous epithelium 
[10].  This random differentiation however causes concern about using undifferentiated 
stem cells in therapeutic treatment [4, 14]. 
 A fourth demonstration of pluripotency involves spontaneous or directed in vitro 
differentiation that can occur in culture.  If the cell culture conditions are altered, such as 
in removal of the feeder layer or LIF, differentiation into a variety of tissue types may 
occur [4]. If the cells are allowed to overgrow past confluency, spontaneous 
differentiation may also occur [10].  In addition, if factors are changed or the cells are 
grown in suspension, the stem cells can clump and form embryoid bodies similar to early 
stage embryos or teratomas which contain a random mixture of differentiated or partially 
differentiated cells that can be further cultured [14]. 
 
Karyotype 
 
 
 Maintenance of a normal karyotype is another important characteristic of most 
stem cell types and is essential if they are to be used for therapeutic applications and for 
most experimental applications.  Only the embryonal carcinoma cell line which is derived 
from the teratocarcinoma generally contains abnormal chromosome numbers [4]. 
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Telomerase Activity 
 
 
High telomerase activity is an additional common characteristic among the stem 
cell types, including mouse and human ES cells [4, 10, 14, 26].  Eukaryotic chromosomes 
are composed of linear, anti-parallel strands of DNA which contain special ends 
containing long arrays of repeating sequences called telomeres.  During normal 
chromosome replication, DNA is copied in the 5’ to 3’ direction with one side being 
copied in a long continuous strand towards the replication fork, called the leading strand, 
and the other strand copied in short segments away from the replication fork, called the 
lagging strand.  Because the polymerase used to copy DNA requires a primer enzyme to 
initiate the DNA replication, a problem occurs for the lagging strand as it reaches the end 
of the DNA where there is no DNA upstream to which the primer may bind.  Replication 
ceases and the newly replicated chromosome from the lagging strand is shorter than the 
original chromosome and continues to become shorter in the telomere region with each 
successive replication [25]. 
Throughout the life of the organism, these chromosomes continue to loose base 
pairs in the telomeric regions and this shortening has been associated with cell death and 
aging.  Research has shown an inverse relationship between the length of the telomeres 
and the age of the individual [25].  If this situation were never corrected, the 
chromosomes of each successive division would be smaller than those of the generation 
before, leading to the potential for increased numbers of genetic abnormalities and 
accelerated aging.  This shortening of the telomeres is a probable explanation for the 
Hayflick limit, which refers to the observation that normally somatic cells will only 
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divide a limited number of times before entering into senescence [10].  For example, in 
culture, human somatic cells only replicate approximately 50 times [15].   
The activation of the enzyme telomerase corrects for this situation, providing 
cellular “immortality”.  Telomerase is a modified reverse transcriptase which acts by 
extending the length of the original or template strand of DNA at its 3’ end.  The 
telomerase enzyme has a RNA associated with it that base pairs with the telomeric 
sequences on the end of the template strand.  Telomerase then extends the template by 
reverse transcription complementary to the RNA template.  The RNA template slips to 
the end of the newly extended segment and the process is repeated.  As this process is 
repeated over and over, a large number of repeating sequences are added to the 
chromosome and the telomeric length is restored [25]. 
Telomerase, however, is not active in all stages of the normal cell cycle.  In 
normal differentiated somatic cells, telomerase is inactive, thus providing the association 
between shortening of the telomeres and aging.  Rather, telomerase activity is generally 
associated with early development and germ line tissue which allows the new individual 
to begin life with normal length chromosomes.  Stem cell research has shown however, 
that telomerase is also active in these cells.  This activity is important in preserving the 
chromosome integrity in these rapidly replicating cells.  Should the stem cells be used in 
therapeutic treatments, it would be important to know that cells from each division were 
identical to normal chromosome composition. 
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Variety of Cell Surface Markers 
 
 
 All cell surfaces have a variety of cell receptors that can be identified and used to 
characterize the cell type.  For example, adipocytes are characterized by adipocyte lipid-
binding protein (ALBP) and fatty acid transporter (FAT).  Stem cells also often display 
patterns of surface markers or receptors that are characteristic of the cell type.  For 
example, the first human ES cell lines isolated by James A. Thomson displayed cell 
markers that were similar to those expressed in human EC and primate ES cell lines.  
These markers included stage-specific embryonic antigen-3 (SSEA-3), SSEA-4, and 
alkaline phosphatase [10].  The stage-specific embryonic antigens are glycoproteins 
which are normally expressed during embryonic development [14].  While alkaline 
phosphatase is also expressed in murine ESC, SSEA-3 and SSEA-4 are not expressed in 
mice past the early cleavage stage embryo [26].  A variety of other cell surface markers 
have been found to be expressed in both human and murine ESC, including CD9, CD81, 
and osteopontin [26]. 
 The amniotic cells isolated to produce AFS cells all expressed c-Kit (CD117), the 
stem cell factor receptor.  Examination of cultures of these cells also found a mixture of 
adult and embryonic cell surface markers, including Class I major histocompatibility 
(MHC) antigens, sometimes MHC II antigens, mesenchymal and/or neural stem cell 
markers (CD29, CD44, CD73, CD90, CD105), and embryonic SSEA-4 (in human AFS 
cells) [20]. 
 The differences in cell surface markers allow researchers to sort cell types based 
on these markers.  Fluorescent labeled monoclonal antibodies specific for the various cell 
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surface markers can be used to label the cells which can then be separated by 
fluorescence-activated cell sorting (FACS). 
 
Potential Stem Cell Applications 
 
 
Developmental Understanding 
 
 
 With the broad range of possible applications, stem cell research has received a 
great deal of focus both within and outside of the scientific community.  One of the most 
basic goals of stem cell research is to increase basic science knowledge of what occurs in 
embryonic development.  Stem cells offer the opportunity to discover the various genes 
and associated factors that play important roles in early development.  This research 
could potentially lead to the development of gene expression maps that would aid in the 
understanding of how the genes influence cell function [4]. 
 Stem cells also provide an opportunity to discover the effects of atypical 
alterations such as in heteroploidy [14].  The affects of teratogens which normally cause 
fetal abnormalities can also be studied with the help of stem cells [4].  These may result 
in discoveries not only concerning birth defects, but also infertility and loss of pregnancy 
[10].  Since many childhood tumors originate from early stages of development, 
developmental stem cell research may also be able to provide insight into the 
mechanisms involved [14]. 
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Repair of Damage Tissue/Organ Transplantation 
 
 
 The greatest proposed application is for the repair or replacement of damaged 
tissue.  Research with stem cells may reveal new growth and differentiation factors that 
will be key in the progress towards directed differentiation or regeneration for medical 
applications [6].  Researchers have been able to manipulate the pluripotent ES cells to 
form at least 20 different tissue types in vitro including adipocytes, cardiomyocytes, 
dendritic cells, endothelial cells, mast cells, neurons, pancreatic islets, and striated muscle 
cells.  The range of tissue types produced has provoked speculation about cures for a 
number of diseases including, but not limited to Parkinson’s disease, diabetes, chronic 
heart disease, cancer, liver failure, multiple sclerosis, spinal cord injuries, and 
Alzheimer’s disease [3, 14]. 
 An additional potential medical application for stem cells is for organs for 
transplantation.  The current supplies of donated organs for those in need are insufficient 
to meet the demand.  The ability to induce differentiation of ES cells has led to the hope 
that researchers will deduce the culture conditions needed to lead to the production not 
only of specific tissues but also organs for transplantation [14].  For example, AFS cells 
have been shown to be able to form tissue-engineered bone within mice with immune 
deficiencies as well as hepatic cells secreting urea [20]. 
 Small changes in culture conditions can influence the differentiation process.  
These changes can involve using different types of feeder cells, different types of culture 
containers, adding growth factors, growth in highly concentrated environments, or 
removal of inhibiting factors such as LIF or feeder cells.  Differentiated cells may also be 
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produced in embryoid bodies and then separated based on surface markers by FACS or 
selected by the use of special culture conditions or drugs [3, 4]. 
 Besides of the lack of available organs, the other greatest problem in tissue 
transplantation is organ compatibility.  Transplantation patients must follow a strict drug 
regiment to prevent immunological rejection of the transplanted tissue despite the 
medical doctor’s best attempt to match tissue types.  With the aid of stem cells, these 
limitations could potentially be overcome. 
 With the developing nuclear transfer cloning technology, it could be possible to 
create a cell line that would be compatible with the tissue type of the patient, an idea 
called “therapeutic cloning” [5].  In nuclear transfer cloning, the nucleus of a normal 
somatic body cell is placed inside of an oocyte that has had the nucleus removed.  The 
environment of the nucleus “reprograms” the somatic nucleus to create a more 
embryonic-like gene expression pattern and can lead to the development of an embryo.  If 
the patient’s own somatic cells were used to create the nuclear transfer clone, ES cells 
could be isolated from the developing blastocyst and used to create immunologically 
matched tissue [29]. 
 There are several problems currently associated with the use of stem cells and 
nuclear transfer technology for the production of immunologically compatible cell lines.  
One major problem is that nuclear transfer is successful in only a small percentage of 
attempts [29].  This could potentially be due to a lack of reprogramming of the Oct-4 
transcription factor gene [27].  In addition, it could be very expensive to create a cell line 
for each patient, in addition to the fact that depending on the urgency of the medical 
condition, there may not be sufficient time. 
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 An alternative solution that is being explored for both general stem cell generation 
and patient specific stem cell production is parthenogentic blastocyst generation.  
Unfertilized eggs activated through chemical treatment rather than through fertilization 
by sperm have been grown to the blastocyst stage so that stem cells could be generated in 
both human and murine samples.  This could be used to create patient specific matches 
(females), closely related matches (family members), or banks of cells for the various 
immunological groups [30, 31]. 
 An alternative might be to create multiple cell lines through traditional methods 
that would closely match the major histocompatibility profiles of multiple patients and 
would adequately meet the needs of most patients.  In addition, there may be ways to 
alter the stem cells to make them more immunologically compatible and less likely to be 
rejected [10]. 
 
 
Drug Development and Other Applications 
 
 
 Molecular techniques that would allow for genetic manipulation of the stem cells 
also open additional doors of research potential.  For example, stem cells could be 
designed that would transport specific DNA segments that would help or completely 
destroy the targeted tissue [6, 14].  In addition, the ability of stem cells to contribute to 
the germ line in chimeric organisms creates the possibility of designing new tailored 
model research organisms which could be useful not only in basic disease research but 
also in drug development [6, 10]. 
 Specific stem cell lines or differentiated tissue, especially from hES cells, could 
be developed and treated to demonstrate the effects or toxicology of the drugs on human 
 28 
tissue rather than only on research animals [14].  Treated differentiated tissue could 
reveal the specific gene effects in a target tissue and identify future gene targets [10]. 
 
Current Obstacles 
 
 
 One major issue that will have to be solved before stem cells can be used in large 
scale clinical applications is how to grow large quantities of identical stem cells.  This is 
made even more difficult by the fact that human stem cell lines grow more slowly than 
the animal models that are currently used in much of research [4].  One possible answer 
to this problem would be to allow the stem cells to partially differentiate into the needed 
progenitor cells and then grow large quantities of the progenitor cells.  Research by 
Shamblott, et al, has shown that the progenitor cells are able to grow well in vitro [32]. 
 An additional problem is that the controlled conditions for the directed 
differentiation of stem cells still need to be determined for most tissue types.  Since 
undifferentiated stem cells can form teratomas when injected into immunocompromised 
research animals, undifferentiated stem cells could also create tumors in 
immunocompromised patients [14]. 
 
Comparison of Stem Cells and Blastocyst 
 While this brief review of literature reflects that much research has focused on the 
development potential of embryonic stem cells and general stem cell characteristics, 
much less research has been done to characterize the transition from the source cell, the 
inner cell mass, to the resulting cell line, the embryonic stem cell.  A National Institute on 
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Aging (NIA) project published in 2003 created cDNA libraries for murine early embryos, 
embryonic and adult stem cells using expressed sequence tags (EST) which were 
subsequently released as clone sets for microarray analysis [33].  Later NIA work 
analyzing gene expression levels as determined by EST frequencies revealed key genes 
common to various cellular and developmental stages (pre-implantation embryos, 
pluripotent stem cells, adult stem cells, etc.), however it failed to directly measure gene 
expression levels or to characterize the blastocyst to stem cell transition [1].  Other 
research did show that the ICM and the ES cells share many common cell surface 
markers [14].   
So while research has focused on characterizing both the blastocyst stage embryos 
and embryonic stem cells, a more extensive analysis of the developmental transition from 
blastocyst to stem cells has not been performed to our knowledge, despite the wide-
spread use of embryonic stem cells.   
 
Potential Techniques 
 For a comparison of differential gene transcription between two sources, a variety 
of methods are available.  With the advent of microarray technology, much research has 
benefited from the vast information provided by this analysis.  The utilization of 
microarrays was prohibited in this research due to procedural costs and quantity of RNA 
required for effective hybridization and analysis.  Standard microarray protocols require a 
minimum of 10-50 ug of total RNA and even the newer improved kits, such as Perkin 
Elmer’s MICROMAXTM TSA Labeling and Detection Kit, required at least 0.5-1 ug of  
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total RNA.  The difficulty and cost in obtaining adequate numbers of embryos made 
microarrays impractical for the proposed research.   
Northern Blots can also be useful for the comparison of isolated RNA between 
samples for specific genes.  However the low levels of RNA made this technique difficult 
and since a broad comparison of gene expression was needed without gene specific 
knowledge, an alternative technique was required. 
Alternative techniques such as the polymerase chain reaction (PCR) or real time 
PCR can also be extremely valuable tools for comparing gene expression between 
samples, however once again for a broad gene expression analysis without specific 
knowledge of which genes should be analyzed, other initial techniques were needed.   
 
Suppression Subtraction Hybridization 
 An alternative method for differential gene transcription analysis is suppression 
subtraction hybridization (SSH) through the use of the CLONTECH PCR-SelectTM 
cDNA Subtraction Kit (Mountain View, CA).  This method compares transcription from 
two sources and combines normalization and subtraction.  It converts source mRNA to 
cDNA, ligating an adaptor to one of the cDNA samples, hybridizing the two cDNA 
samples, removing the hybridized cDNAs, and amplifying the unhybridized cDNA 
samples containing the adaptor.  The procedure is repeated, switching the sample that 
contains the adaptor, so that all uniquely expressed genes in either sample may be 
identified (Figure 2.1).   
First described in 1996 by Diatchenko, et al [34], SSH has proven effective in 
numerous other research projects and has demonstrated its ability to identify uniquely 
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expressed genes between samples.  For example, it has been used to study gene 
expression within the mouse oviduct during the preimplantation period [35], within 
maturing bovine oocytes [36], within murine oocytes and early embryos in order to 
characterize the maternal-to zygotic transition [37, 38], and to study the effect of 
differential gene expression, such as with Oct-4 [39]. 
The CLONTECH PCR-SelectTM cDNA Subtraction Kit requires 0.5-2 µg of poly 
A+ RNA, an amount that can still be difficult to obtain from embryos.  The limitation of 
RNA required can be overcome by the utilization of CLONTECH’s Super SMARTTM 
PCR cDNA Synthesis Kit, which has been designed to use small amounts of RNA in a 
PCR based process to produce high quality cDNA which can then be used with the 
CLONTECH PCR-SelectTM cDNA Subtraction Kit.  The Super SMARTTM PCR cDNA 
Synthesis Kit requires only 2 ng of total RNA, making this an effective procedure for 
differential gene expression analysis of murine blastocyst and embryonic stem cells [40]. 
 In the production of the cDNA samples, special techniques must be used.  One 
problem that has typically occurred in cDNA production is the under representation of 
sequence on the 5’ end of the RNA due to the difficulty in transcribing the entire 
sequence by reverse transcriptase (RT).  In this process, a modified oligo(dT) primer (the 
CDS primer), primes the synthesis of the first strand and as the RT reaches the 5’ end of 
the mRNA, it adds an extra 3-5 nucleotides, typically deoxycytidine.  The SMARTTM 
oligonucleotide primer contains an oligo(G) sequence which allows it to bind to the 
oligo(C) stretch providing opportunity for full strand replication.  The RT switches 
strands and completes the double-stranded molecule.  The poly(A) sequence and the 
SMART anchor sequence are then valuable primer sites for total cDNA amplification.  
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The CDS primer and SMART oligonucleotide primer both contain a Rsa I site so that 
these sequences may later be removed (Figure 2.2) [41]. 
 In general PCR (which is not subtractive), the products are often produced in 
proportion to the original amount of cDNA present in the sample.  This makes it difficult 
to identify genes that are differentially expressed in low quantities.  The normalization 
that occurs in suppression subtraction removes the cDNAs that are more commonly 
expressed in higher quantities, allowing better identification of weakly expressed genes 
[42]. 
 The first hybridization accomplishes equalization and enrichment of differentially 
expressed sequences (Figure 2.1).  The procedure begins with two cDNA samples from 
the same source, called the tester samples (experimental samples), but with a different 
adaptor molecule annealed to each sample.  An excess of driver (control sample) is added 
to each sample separately and the samples are heat denatured and allowed to anneal.  
More abundant molecules anneal faster which causes equalization or normalization in the 
“a” type molecule of high and low abundance sequences.  Products are: 
 “a” – Unique high and low abundance tester sequences 
 “b” – High abundance tester sequences with the same adaptor 
 “c” – Common tester and driver sequences – only 1 adaptor 
 “d” – Driver cDNA with no adaptor 
 The second hybridization generates templates for PCR amplification from 
differentially expressed sequences. The two hybridized samples are mixed together 
without denaturing, which produces a new “e” molecule, which consists of the joining of 
the type “a” molecule from both samples having different adaptors.  DNA polymerase 
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fills in the ends and the type “e” molecules have different annealing sites for nested 
primers on the 5’ and 3’ ends. 
 “e” – Differentially expressed tester sequences 
 The first PCR amplification is suppression PCR so that only differentially 
expressed sequences are amplified. 
 “a” – Missing primer annealing sites and can’t be amplified. 
“b” – Most form pan-like structures so that they can’t be exponentially amplified. 
“c” – Have only one primer site allowing only linear amplification. 
“d” – Missing primer annealing sites and can’t be amplified. 
“e” – Has two different adaptors and is exponentially amplified. 
In the second PCR amplification, the background is reduced and differentially expressed 
sequences are further enriched through the use of the nested primers (Figure 2.1) [42]. 
 
Subsequent Techniques 
 Once suppression subtraction hybridization is used to isolate the differentially 
expressed gene fragments, the unique fragments must be cloned, sequenced, and 
identified through online database searches.  Since SSH has been found to generate about 
2% false positives, the unique expression of sequenced genes needs to also be 
subsequently confirmed [43].  While Northern blots can be used for conformational 
analysis, it is prohibited once again by limited sample availability.  Reverse-transcriptase 
polymerase chain reaction (RT-PCR) is possible with small test samples and will be used 
to first confirm differential expression of the isolated sequences between the original test 
 34 
samples.  Subsequently, selected confirmed differentially expressed segments will be 
quantified between samples through use of the real time polymerase chain reaction. 
 
Research Focus 
 While the stem cell literature reflects a great deal of focus on stem cell 
characteristics as well as potential research and therapeutic applications, little has been 
done to characterize the transition from blastocyst stage embryo to embryonic stem cell.  
With the current limitations on available hES cell research and the limited number of 
viable stem cell lines, avenues to alternative sources of pluripotent stem cells need to be 
explored.  Characterizing the blastocyst to ESC transition will provide basic 
developmental information on key stem cell genes that will give greater understanding to 
this transitional process and may aid both in monitoring the quality of new stem cell lines 
as well as in the potential development of future stem cell lines. 
 Murine embryos and embryonic stem cell lines were used for this project as they 
are readily available and have proved to be useful research models in numerous stem cell 
experiments.  While murine stem cells are not identical to human stem cells and perfect 
correlations can’t always be made, they do share a great number of basic characteristics 
and murine samples lack the ethical and availability concerns of human samples [26]. 
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Figure 2.1 Suppression Subtraction Hybridization Differential Gene Amplification.  
Taken from [42].
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Figure 2.2 Suppression Subtraction Hybridization cDNA Production.   
Taken from [40]. 
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CHAPTER III 
 
 
METHODOLOGY 
 In this study, four SSH comparisons were made - blastocyst vs. blastocyst, 
trophectoderm vs. blastocyst, 129SvEv stem cells vs. fibroblast feeder cells, and 
blastocyst vs. 129SvEv stem cells.    The first three comparisons served as control 
comparisons while the last comparison was the primary comparison of interest.   
Blastocyst vs. blastocyst was a control on the SSH procedure since in a 
comparison between the same source samples, one should not expect to see any genes 
amplified as uniquely expressed.  The 129SvEv ESC vs. fibroblast feeder cell comparison 
served as a control as few unique transcripts should be identifiable in the fibroblast 
sample since these cells had been irradiated and should be generally inactive.  However 
since the ESC sample would naturally be contaminated with small amounts of fibroblast 
due to common culturing techniques, the possibility of identifying unique transcripts in 
the ECS which had originated from the fibroblast contamination needed to be eliminated. 
Similarly, the comparison of trophectoderm vs. blastocyst served to identify 
whether or not there were any major differences in gene expression in the trophectoderm 
in comparison to the blastocyst.  Since embryonic stem cells are produced from the inner 
cell mass cells of the cultured blastocyst, the goal of the research was to identify genes 
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directly involved in ESC formation and differential expression originating from the 
trophectoderm needed to be eliminated.    
 
Sample Collection 
Blastocyts 
 Four week old female CD1 mice were superovulated with injections of 7.51 
international units (IU) pregnant mare serum gonadotrophin (PMSG; Sigma, St. Louis, 
MO) followed two days later with 7.51 IU human chorionic gonadotrophin (hCG; Sigma) 
and overnight placement with CD1 breeder males.  Oviducts of females who showed 
evidence of copulation by the presence of vaginal plugs the following morning were 
collected and flushed at 3.5 days post-copulation into a 37oC solution of phosphate 
buffered saline (PBS) with 3 mg/ml bovine serum albumin (BSA; Irvine Scientific, Santa 
Ana, CA). 
 The blastocysts were washed in 37oC PBS/BSA followed by the removal of the 
zona pellucidas in acid Tyrodes medium at 37oC (pH 2.5; Sigma).  A second washing in 
37oC PBS/BSA (40 µl drop) was followed by washes in serum free BWW (Biggers, 
Whitten, and Whittingham; Irvine Scientific) and a 40 µl drop of BWW/Hepes with 
RNasin (SUPERase-In, 1U/µl; Ambion, Austin, TX).  A total of 176 blastocysts were 
obtained from 15 mice and processed immediately for RNA as a group.  Following RNA 
isolation, the pool was divided into 6 samples for the remainder of the experiment. 
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Trophectoderm 
  Blastocysts were collected from 10 CD1 mice superovulated as previously 
described.  Once the blastocysts were flushed from the oviducts, they were immediately 
placed in BWW Hepes medium (50 µl drop) and manually bisected at 50X magnification 
by use of a stereomicroscope to remove the portion containing the inner cell mass.  A 
total of 47 trophectoderm samples were obtained from a pool of 78 blastocysts.  Fetal 
bovine serum (FBS; 5 µl; HyClone, Logan, UT) was added to the drop to release the 
electrostatic charge and the pure trophectoderm portions were removed and immediately 
processed for RNA. 
 
Stem Cells and Feeder Cells 
 Samples in the form of frozen cell pellets of 129 SvEv murine embryonic stem 
cells (1.1 x 107  cells) and irradiated embryonic murine fibroblast feeder cells (2 x 106 
cells) were obtained from Ute Hochgeschwender at the Oklahoma Medical Research 
Foundation. The pellets were resuspended in 200 µl of PBS and processed for RNA. 
 
RNA Extraction 
Blastocysts and Trophectoderm 
 RNA was isolated from the blastocyst and trophectoderm samples using the 
NucleoSpin RNA and Virus Purification Kit (Clontech, Mountain View, CA).  Samples 
to be processed were placed in 175 µl of cell lysis buffer.  1.75 µl of β-mercaptoethanol 
 40 
was added and the samples were mixed by pipetting and vortexing.  175 µl of 70% 
ethanol was added to the samples and the tubes were again vortexed.  The samples were 
placed in a NucleoSpin column (Clontech) and centrifuged at 8,000 g for 30 seconds.  
Once the flowthrough was discarded, 175 µl of membrane desalting buffer was added to 
the column, and the tube was centrifuged at 11,000 g for 1 minute.  After discarding the 
flowthrough, DNase I (50 µl; Clontech) was added to the column and incubated for 15 
minutes at room temperature.  100 µl of wash buffer I was added and the column was 
centrifuged at 8,000 g for 30 seconds.  The flowthrough was discarded, 300 µl of wash 
buffer II was added, and the column was centrifuged at 8,000 g for 30 seconds.  A second 
wash was performed using 125 µl of wash buffer II followed by centrifugation at 11,000 
g for 2 minutes.  The sample RNA was eluted by adding 30 µl of nuclease-free water, 
centrifuging at 11,000 g for 1 minute, and repeating a second time.  RNA concentrations 
were determined by UV spectroscopy and the samples were frozen at -80oC. 
 
Stem Cells and Feeder Cells 
 The stem cell samples and feeder cells were processed using the same NucleoSpin 
RNA Kit.  Cell lysis buffer (700 µl) was added directly to the samples which had been 
resuspended in PBS.  After β-mercaptoethanol (7 µl) was added to the samples and 
vortexed, the samples were split in half and centrifuged in NucleoSpin Filter units 
(Clontech) at 11,000 g for 1 minute in order to reduce the viscosity.  Each sample was 
then processed as previously described from the addition of the 70% ethanol to the final 
rinse with wash buffer II with the exception that the volumes of all added reagents were 
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doubled due to the increased cell concentrations.  The samples were then eluted with 2 
washes of 40 µl of water.  Concentrations were once again determined by UV 
spectroscopy and the samples were frozen at -80oC. 
 
Sample cDNA Synthesis 
Blastocysts and Trophectoderm 
 The blastocyst and trophectoderm samples had limited availability and therefore 
were processed from RNA to cDNA using the SuperSMART PCR cDNA Synthesis Kit 
(Clontech) according to the manufacturer’s protocol.  This kit allows SSH users to begin 
with as little as 10 ng of total RNA, however the blastocyst samples began with 
approximately 230 ng of total RNA and the trophectoderm sample began with 300 ng of 
total RNA.  In brief, a 2 minute denaturation at 65oC was followed by first strand 
synthesis at 42oC for 90 minutes.  The reaction primer, 3’ SMART cDNA synthesis 
(CDS) primer, is an oligo-dT primer which only allows for mRNA amplification.  A 
SMART II A oligonucleotide is also included which pairs with additional cytosine 
nucleotides added to the 5’ end of the mRNA by the terminal transferase action of the 
reverse transcriptase (RT).  This allows the RT to switch templates providing for total 
replication of the mRNA 5’ end.  In addition, both the CDS primer and the SMART II A 
oligonucleotide contain a primer amplification site that allows for future exponential 
amplification.  Following first strand cDNA synthesis, the products are purified in a 
NucleoSpin Extraction Spin Column (Clontech) to remove cDNA fragments less that 100 
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base pairs as well as unincorporated nucleotides.  The samples were eluted in 80-85 µl of 
water. 
 The cDNA synthesis was completed by an optimized PCR protocol in 
continuance of the SuperSMART protocol using the Advantage 2 PCR Kit (Clontech).  
Three tubes containing 27 µl of first strand cDNA product were set up for each sample 
and one of the tubes was used to determine the optimal number of amplification cycles.  
Aliquots were pulled every three cycles from cycle 15 through 30 and analyzed on a 
1.2% TAE agarose gel.  The blastocyst sample was optimized at 23 cycles while the 
trophectoderm was optimized at 27 cycles.  The remaining two samples were amplified 
for the optimized number of cycles in the Perkin-Elmer 9600 thermal cycler (Applied 
Biosystems, Foster City, CA).  Parameters were an intial denaturation of 95oC for 1 
minute followed by the optimized number of cycles of 95oC for 5 seconds, 65oC for 5 
seconds, and 68oC for 6 minutes.  Aliquots (5 µl) of each sample were analyzed on a 
1.2% TAE agarose gel and the tubes were combined for each sample. 
  Following PCR, the amplified products were purified with an equal volume of 
phenol:choloroform:isoamyl alcohol (25:24:1) and concentrated with 700 µl of n-butanol.  
The samples were further purified using the Clontech CHROMA SPIN-1000 columns 
according to the Super SMART PCR cDNA Synthesis Kit protocol.  The columns are 
optimized for purifying fragments greater than 1,350 bases while remove proteins, 
enzymes, primers, excess dNTPs, and small nucleotide fragments.  Presence of the PCR 
product was confirmed in the final sample by analyzing aliquots on a 1.2% TAE agarose 
gel. 
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 In preparation for the subtraction protocol, the purified PCR product was digested 
with Rsa I  at 37oC for 3+ hours to create short, blunt-ended DNA fragments.  During the 
subtraction protocol, the blunt ends are needed for adaptor ligation and subsequent 
subtraction.  In addition, the digestion removed the SMART II A oligonucleotide and the 
3’ SMART CDS Primer II A from the amplicons since each contains an Rsa I site.  The 
reaction was analyzed with 10 µl aliquots on a 1.2% TAE agarose gel and subsequently 
stopped with the addition of 8 µl of 0.5 M ethylenediaminetetraacetic acid (EDTA). 
 Digested samples were purified using the QIAquick PCR Purification Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s protocol.   Briefly, Buffer PB 
and the digested samples were combined in a 5:1 ratio, mixed, and filtered through a 
QIAquick spin column (750 µl at a time) by centrifugation at approximately 10,000 g for 
60 seconds.  Flow-through was discarded and the column filter was washed with 0.75 ml 
of Buffer PE and centrifuged at 10,000 g for 60 seconds.  The flow-through was 
discarded and the column centrifuged for an additional minute at 10,000 g.  Purified, 
digested DNA samples were eluted by applying 50 µl of TE (10 mM Tris-Cl, 1 mM 
EDTA, pH 8.0) to the center of the membranes, allowing them to stand for 1 minute, and 
centrifuging at 10,000 g for 1 minute.  Subsequently, the purified samples were processed 
according to the Super SMART PCR Synthesis Kit User Manual. 
 Eluted samples were applied to a microfiltration column (Clontech) and 
centrifuged for 5 minutes at 10,000 g.  Precipitation of the collected sample was 
performed with the addition of 50 µl of 4 M ammonium acetate (Clontech) and 375 µl of 
95% ethanol followed by vortexing and centrifugation at 16,000 g for 10 minutes.  The 
supernatant was discarded, 500 µl of 80% ethanol was added, and the tube was 
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centrifuged for 10 minutes at 16,000 g.  Once again, the supernatant was discarded and 
dried pellets were resuspended in 6.7 µl of 1X TNE buffer (10 mM Tris-HCl [pH 8], 10 
mM NaCl, 0.1 mM EDTA).   
 Aliquots of the DNA samples (1.2 µl in 11 µl of water) were used to determine 
the DNA concentration by UV spectrophotometry.  The two blastocysts samples for the 
blastocyst versus blastocyst comparison had high concentrations and were diluted to the 
maximum protocol concentration of 300 ng/µl.  The third blastocyst sample had a 
concentration of 290.3 ng/µl and the trophectoderm sample had a concentration of 297.6 
ng/µl and therefore neither was diluted.  The final samples were then ready for adaptor 
ligation. 
 
Stem Cells and Feeder Cells 
 The stem cells and feeder cells were available in larger quantities than the 
embryonic cells and therefore were processed to cDNA using the Clontech PCR-SelectTM 
cDNA Subtraction Kit according to the provided protocol.  As directed in the protocol, a 
supplied control Poly A+ RNA sample from human skeletal muscle was processed along 
with the experimental samples to verify protocol success. 
 In brief, 2 µg of RNA from each sample was combined with cDNA Synthesis 
Primer (10 µM; Clontech) and incubated at 70oC for 2 minutes, followed by 2 minutes on 
ice.  Following brief centrifugation, 5X First-Strand Buffer (Clontech), dNTP mix (10 
mM each; Clontech), water, and AMV Reverse Transcriptase (20 units/µl; Clontech) 
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were added to each sample and incubated at 42oC for 1.5 hours to complete first strand 
cDNA synthesis.   
 The samples were placed on ice to terminate the first strand synthesis and were 
immediately processed for second strand synthesis.  Water, 5X Second-Strand Buffer 
(Clontech), dNTP mix (10 mM; Clontech), and 20X Second-Strand Enzyme Cocktail 
(Clontech) were added to the tubes for a total volume of 80 µl.  Following incubation at 
16oC for 2 hours, T4 DNA Polymerase (6 units; Clontech) was added to each sample and 
incubated at 16oC for an additional 30 minutes.  Second strand synthesis was terminated 
with the addition of 4 µl of 20X EDTA/Glycogen mix (0.2 M EDTA; 1 mg/ml glycogen; 
Clontech). 
 The samples were extracted with 100 µl of phenol:chloroform:isoamyl alcohol 
(25:24:1) followed by two cycles of 100 µl of cholorform:isoamyl alcohol (24:1).  
Sample precipitation was obtained with the addition of 40 µl of 4M ammonium acetate 
and 300 µl of 100% ethanol.  Following 20 minutes of centrifugation at 16,000 g, the 
pellet was washed twice with the addition of 500 µl of 70% ethanol and centrifugation for 
10 minutes at 16,000 g.  The pellets were dissolved in 50 µl of water and then proceeded 
to an Rsa I digestion. 
 Each DNA sample was digested with Rsa I (10 units/µl; Promega, Madison, WI) 
for 1.5 hours at 37oC.  Addition of 2.5 µl of 20X EDTA/Glycogen mix terminated the 
reaction and the digested samples were extracted twice each with the addition of 50 µl of 
phenol:chloroform:isoamyl alcohol (25:24:1) followed by the addition of 50 µl of 
chloroform:isoamyl alcohol (24:1).  Extracted samples were precipitated by the addition 
of 25 µl of 4M ammonium acetate and 187.5 µl of 100% ethanol and centrifugation for 
 46 
20 minutes at 16,000 g.  The pellets were washed with the addition of 200 µl of 70% 
ethanol and centrifugation followed by 100 µl of 70% ethanol.  DNA samples were 
resuspended in 5.5 µl of water and were then ready for adaptor ligation. 
 
Suppression Subtraction Hybridization 
 The cDNA samples prepared for the blastocyst, trophectoderm, stem cells, and 
feeder cells through the Super SMARTTM PCR cDNA Synthesis Kit and the Clontech 
PCR-SelectTM cDNA Subtraction Kit were processed in a pair-wise fashion beginning 
with the adaptor ligation step of the Clontech PCR-SelectTM cDNA Subtraction Kit.  The 
four comparisons being performed were blastocyst versus blastocyst, trophectoderm 
versus blastocysts, blastocyst versus stem cell, and stem cell versus feeder cell.  Both the 
blastocysts versus blastocyst and the stem cell versus the feeder cells served as control 
comparisons. 
 For each pair, the comparison was performed twice.  First one of the comparison 
samples served as the “tester” or experimental sample while the second sample served as 
the “driver” or control sample.  A second comparison with the tester and driver samples 
reversed was then performed allowing for identification of uniquely expressed genes in 
both samples.  
 In the adaptor ligation protocol, the tester cDNA sample was divided into two 
aliquots.  Each aliquot was ligated to either the adaptor with the forward primer site 
(Adaptor 1) or the adaptor with the reverse primer (Adaptor 2R).  A control tester sample 
ligated to both adaptors was also created.  The ligation protocol in brief was as follows. 
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 Each experimental tester cDNA sample was diluted by adding 1 µl to 5 µl of 
water.  A ligation master mix was made with the following reagents for each reaction: 
water (3 µl), 5X Ligation buffer (2 µl; Clontech), and T3 DNA Ligase (1 µl of 400 
units/µl; Clontech).  Each tester cDNA was then ligated to each adaptor.  For Adaptor 1, 
2 µl of diluted cDNA was mixed with 2 µl of Adaptor 1 (10 µM; Clontech) and 6 µl of 
the Master Mix.  For Adaptor 2R, 2 µl of the diluted cDNA was mixed with 2 µl of 
Adaptor 2R and 6 µl of the Master Mix.  A third ligation tube was then set up combining 
2 µl of each of the adaptor reaction mixtures in order to serve as the unsubtracted tester 
control.   
 Following mixing, each adaptor ligation tube was incubated at 16oC overnight (~ 
12 hours).  The reactions were stopped with the addition of 1 µl of 20X EDTA/Glycogen 
mix and the ligase was heat inactivated by incubation at 72oC for 5 minutes.   
 The ligation efficiency was analyzed for each reaction through PCR using 
G3PDH (glyceraldehyde-3-phosphate dehydrogenase; also known as GAPDH) primers 
and gel electrophoresis.  G3PDH is considered a housekeeping gene that is constitutively 
expressed in all tissues and therefore should be present in each test sample.  Four tubes 
were set up for each experimental and control cDNA sample.  Tube 1 contained 1 µl of 
the tester ligated to Adaptor 1, 1 µl of the G3PDH 3’ Primer (10 µM; Clontech), and 1 µl 
of the PCR Primer 1 (10 µM; Clontech).  Tube 2 contained 1 µl of the tester ligated to 
Adaptor 1, 1 µl of the G3PDH 3’ primer, and 1 µl of the G3PDH 5’ primer.  Tube 3 
contained 1 µl of the tester ligated to Adaptor 2R, 1 µl of G3PDH 3’ Primer, and 1 µl of 
PCR Primer 1.  Tube 4 contained 1 µl of the tester ligated to Adaptor 2R, 1 µl of G3PDH 
3’ Primer, and 1 µl of G3PDH 5’ Primer.  A master mix was made for each reaction 
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containing 18.5 µl of water, 2.5 µl of 10X PCR reaction buffer, 0.5 µl dNTP mix (10 
mM), and 50X Advantage cDNA Polymerase mix (Clontech).  The 22 µl of master mix 
was added to each of the previous four tubes and incubated for 5 minutes at 75oC to 
extend both adaptors.  PCR was begun by 30 seconds at 94oC followed by 25 cycles of 10 
seconds at 94oC, 30 seconds at 65oC, and 2.5 minutes at 68oC.  Gel electrophoresis was 
subsequently performed on a 2.0% TAE agarose gel with 5 µl aliquots from each 
reaction. 
 Following verification of successful ligation, the first pair-wise hybridization was 
performed for each comparison in two separate tubes.  In this protocol, driver and tester 
samples are mixed, heat denatured, and allowed to mix.  The single stranded cDNAs that 
remain at the end of the reaction contain increased concentrations of differentially 
expressed genes and are available for binding in the second hybridization. 
For the first hybridization, the first tube contained 1.5 µl of driver cDNA, 1.5 µl 
of adaptor 1 ligated tester cDNA, and 1 µl of 4X Hybridization Buffer (Clontech).  A 
second tube contained 1.5 µl of driver cDNA, 1.5 µl of adaptor 2R ligated tester cDNA, 
and 1 µl of 4 X Hybridization Buffer.  Both sample tubes were incubated at 98oC for 1.5 
minutes followed by 8-12 hours of incubation at 68oC.  Upon completion of the first 
hybridization, the samples were immediately processed for the second hybridization. 
 In the second hybridization, additional driver was denatured by mixing 1 µl of 
driver cDNA, with 1 µl of 4X Hybridization Buffer and 2 µl of water followed by 
incubation for 1.5 minutes at 98oC.  Denatured driver and the two samples from the first 
hybridization were mixed simultaneously together and incubated at 68oC overnight.  
Following the incubation, 200 µl of the dilution buffer was added and the sample was 
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incubated at 68oC for an additional 7 minutes.  The resulting hybridized molecules 
contained the differentially expressed cDNAs with different adaptors (Adaptor 1 and 
Adaptor 2R) on each end.  These samples were then amplified through PCR. 
 PCR was performed for each hybridized sample, the unsubtracted tester control, 
and the PCR control subtracted cDNA provided in the kit.  A master mix for each 
reaction was made containing 19.5 µl of water, 2.5 µl of 10X PCR reaction buffer 
(Clontech), 0.5 µl dNTP mix (10 mM; Clontech), 1.0 µl PCR Primer 1 (10 µM; 
Clontech), and 0.5 µl 50X Advantage cDNA polymerase mix.  24 µl of the master mix 
was added to 1 µl of each reaction sample and incubated at 75oC for 5 minutes in order to 
complete the missing adaptor strands.  PCR was then performed in the Perkin-Elmer 
GeneAmp PCR System 9600 with 25 seconds at 94oC followed by 27 cycles of 10 
seconds at 94oC, 30 seconds at 66oC, and 1.5 minutes at 72oC.  The final products were 
analyzed on a 2.0% TAE agarose gel. 
 Product from the primary PCR was diluted by adding 3 µl to 27 µl of water.  The 
diluted PCR product was then used in a secondary PCR reaction using nested primers in 
order to further select for the differentially expressed cDNAs while also decreasing any 
background product.  A master mix for each reaction was mixed containing 18.5 µl 
water, 2.5 µl of 10 PCR reaction buffer, 1.0 µl of Nested PCR primer 1 (10 µM; 
Clontech), 1.0 µl of Nested PCR primer 2R (10 µM; Clontech), 0.5 µl dNTP mix (10 
mM), and 0.5 µl of 50X Advantage cDNA polymerase mix.  24 µl of the master mix was 
added to 1 µl of the diluted primary PCR product and amplified in the Perkin-Elmer 9600 
for 10 cycles of 94oC for 10 seconds, 68oC for 30 seconds, and 72oC for 1.5 minutes.  The 
final products were analyzed on a 2.0% TAE agarose gel. 
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 A final subtraction efficiency PCR was performed to analyze the resulting PCR 
products using the G3PDH housekeeping gene previously used in the ligation efficiency 
test.  Subtracted and unsubtracted PCR products were diluted 10 fold based on DNA 
concentration.  A reaction tube for each diluted product was mixed containing 1 µl of 
diluted cDNA, 1.2 µl of G3PDH 3’ Primer (10 µM), 1.2 µl of G3PDH 5’ Primer (10 
µM), 22.4 µl water, 3.0 µl 10X PCR reaction buffer, 0.6 µl dNTP mix (10 mM), and 0.6 
µl 50X Advantage cDNA Polymerase mix.  The reaction was amplified in the Genemate 
Genius Thermal Cycler for 33 cycles of 30 seconds at 94oC, 30 seconds at 60oC, and 2 
minutes at 68oC.  After cycles 18, 23, 28, and 33, 5 µl of each amplified product was 
removed from the reaction tube.  Following completion of the PCR, each 5 µl sample was 
analyzed on a 2.0 % TAE agarose gel for evidence of a decrease of G3PDH in subtracted 
products in comparison to the unsubtracted samples. 
 
Cloning and Sequencing of Subtracted cDNA 
 Upon amplification of the uniquely expressed cDNA sequences through the 
suppression subtraction hybridization protocol, the secondary PCR products were cloned 
using one of two methods.  Initially, amplified products from the blastocyst and stem cell 
comparison were cloned into pBluescript II SK (+) (Stratagene, La Jolla, CA) and placed 
into TOP 10F’ E. coli (Stratagene).  In brief, the amplified cDNA and the plasmid were 
restriction digested with both Sma I and Eag I (New England Biolabs, Ipswich, MA) to 
produce complementary DNA ends.  Subsequently the plasmid and digested cDNA were 
ligated in reactions set up in 1:1, 1:2, and 1:3 ratios, placed into the TOP 10F’ cells, and 
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plated on 2YT (Amp 100) agar plates.  (The plasmid contained an ampicillin resistance 
gene.)  Following overnight incubation at 37oC, colonies were picked, grown overnight in 
2YT broth, and miniprepped using a standard plasmid isolation protocol. 
Subsequently, additional products from all of the comparisons except for 
blastocyst versus blastocyst (which as a control reaction wasn’t cloned) were cloned into 
the TOPO TA Cloning Kit for Sequencing (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s protocol.  The included vector, pCR®4-TOPO®, contained a 3’ thymidine 
overhang making it compatible for ligation with PCR products produced with Taq 
polymerase which adds a deoxyadenosine overhang to its PCR amplicons.  Insertion of 
the DNA segment into the vector disrupts the expression of a lethal ccdB gene, so that 
only the TOP10 E. coli cells containing recombinant vectors are allowed to grow, 
eliminating the need for blue-white screening as in other protocols. 
 The TOPO cloning procedure in brief is as follows.  The cloning reaction was 
mixed containing 4 µl of fresh secondary PCR product, 1 µl of salt solution (1.2 M NaCl, 
0.06 M MgCl2; Invitrogen), and 1 µl of the TOPO vector (10 ng/µl; Invitrogen) and 
incubated for 30 minutes at room temperature followed with placement on ice.  For the 
transformation, 2 µl of the cloning reaction was gently mixed with one vial (50 µl) of the 
One Shot® Chemically Competent E. coli (Invitrogen) and placed on ice for 5 minutes.  
The tube was subsequently heat-shocked for 30 seconds at 42oC followed by placement 
on ice.  250 µl of S.O.C. (Super Optimal Catabolite Repression Broth) medium (2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
20 mM glucose; Invitrogen) was added to the reaction and the tube was shaken 
horizontally (200 rpm) for 1 hour at 37oC.  Colonies were grown overnight on LB (Luria-
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Bertani) agar plates containing 100 µg/ml of ampicillin.  Selected colonies were 
subsequently grown overnight in LB broth containing 100 µg/ml of ampicillin.  The 
plasmids were extracted from the cultures using a standard min-prep protocol and 
quantified by UV spectrophotometry.   
Plasmid inserts were then sequenced by the Oklahoma State University 
Recombinant DNA/Protein Resources Facility and the sequences were analyzed using 
BioEdit 5.0.9 [44].  The identity of each sequence was obtained through use of the 
National Center for Biotechnology Information (NCBI) Basic Local Alignment Search 
Tool (BLAST) which compares the given nucleotide sequence with those of known 
sequences within their GenBank database (Bethesda, MD) and determines the statistical 
significance of any matches. 
 
Confirmation Through PCR 
 From the identified cloned inserts, primers were designed for 22 sequences (Table 
3.1) that were of non-ribosomal origin using the Primer Select portion of the Lasergene 
sequence analysis software [45] and obtained from Invitrogen.  RNA from the original 
samples was converted to cDNA in a reverse transcriptase reaction.  In addition, a second 
type of stem cell, C57BL/6, was also used as a PCR sample in order to verify the validity 
of the results in other strains of murine stem cells.   
For the reverse transcriptase reactions, 1.5 µl of random decamer primer (150 
ng/µl; Invitrogen), 5-6 µl of RNA (5 µg), and water were mixed in an 11 µl reaction and 
incubated at 70oC for 10 minutes.  Following placement on ice and a brief centrifuge, 4 
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µl of 5X First Strand Buffer (Clontech), 2 µl of dNTP mix (10 mM each; Clontech), 2 µl 
of DTT (dithiothreitol; 100 mM; Clontech), and 1 µl of PowerScript RT (Clontech) were 
added.  The reaction was incubated at 42oC for 90 minutes followed by heating at 70oC 
for 15 minutes. 
 PCR and agarose gel electrophoresis was subsequently performed to confirm 
expression patterns for the 22 DNA sequences.  The reactions consisted of 0.5 µl cDNA 
(0.25 µg/µl), 17.0 µl of water, 2.5 µl 10X Advantage 2 PCR Buffer (Clontech), 0.5 µl 
50X dNTPs (10 mM each; Clontech), 2.0 µl of each primer (10 µM; Invitrogen), and 0.5 
µl 50X Advantage 2 Polymerase (Clontech).  The cycling parameters in general were an 
initial denaturation at 95oC for 1 minute, followed by 30 cycles of 95oC for 30 seconds, 
58oC for 30 seconds, and 68oC for 1 minute.  A final extension was performed at 68oC for 
1 minute.   
 
Quantification with Real Time Polymerase Chain Reaction 
 From the identified uniquely expressed DNA segments, three genes of interest 
were selected for additional quantitative study of the expression patterns through the real 
time polymerase chain reaction (qPCR).  The three genes, peroxiredoxin 1 (Prdx 1), 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein (Ywhaz), and 
voltage-dependent anion channel 3 (Vdacs3), were all three found to be uniquely 
expressed in the blastocyst versus embryonic stem cell comparison, the main comparison 
of interest. 
 In addition to the three genes of interest, reactions were also run from each 
sample for ribosomal 18s (r18s), a housekeeping gene used as a standard of comparison 
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for relative quantification.  The real time reactions were semi-quantitative rather than 
quantitative in that the original number of transcripts for each gene was not absolutely 
measured but was measured in comparison to the expression of the r18s gene.   
 For the real time PCR, new stem cell, feeder cell, and blastocyst samples were 
collected and processed to RNA as previously described.  Initial quantities of cells were 1 
x 107 for the 129 SvEv stem cells, 1.8 x 106 for the irradiated mouse embryonic fibroblast 
feeder cells, and 20 blastocysts.   The gene expression levels were also analyzed in a 
second strain of murine stem cell, C57BL/6, whose initial quantity was 1.25 x 107.  
Following RNA isolation, cDNA was produced using the reverse transcriptase procedure 
previously described.   
 For the qPRC reaction, primers were designed for the three genes using Primer 
Select and obtained from Invitrogen (Table 3.2).  The r18s primers utilized were 
originally designed by Dr. Marino in the lab of Dr. Miller at the University of Tulsa [46].  
The specificity of all four sets of primers was checked through NCBI Blast searches.    
Real time PCR was subsequently performed using the DyNAmoTM HS SYBR Green 
qPCR Kit (Finnzymes, Finland) in the DNA Engine Opticon 2 (BioRad, Hercules, CA).  
In the DyNAmo HS SYBR Green kit, SYBR Green 1 fluorescent dye emits fluorescence 
when bound to the double-stranded amplicons and therefore produces increasing 
fluorescence with each additional PCR cycle.   
For each reaction, 1 µl of template cDNA (0.25 µg/ul), 0.75 µl of each primer (10 
µM; Invitrogen), 12.5 µl 2X Master Mix (Finnzymes), and 10 µl of water were used.  The 
2X Master Mix contained modified DyNAmo hot start DNA polymerase, SYBR Green 1, 
optimized PCR buffer, 5 mM MgCl2, and a dNTP mix.  General reaction parameters were 
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95oC for 15 minutes followed by 43 cycles of 94oC for 20 seconds, 53-55oC for 45 
seconds, 72oC for 45 seconds, 76oC for 1 second with plate read, and 78oC for 1 second 
with plate read.  A melting curve from 50oC to 90oC was also performed for each 
reaction.  Reactions were performed twice with duplicate wells (for a total of 4 data sets 
for each gene per sample) and with control reactions in each amplification run.  The 
control reactions included no reverse transcriptase samples and no template reactions. 
Following completion of the real time PCR reactions, the threshold (CT) number 
was determined for each sample reading of the four genes.  The CT number for each of 
the three genes of interest in each sample was compared with the CT number for the r18s 
housekeeping gene in that sample in order to calculate the fold difference of expression.  
Specifically, the delta CT (∆CT) was calculated by subtracting the control r18s CT from 
the experimental gene CT value for each reading.  These ∆CT values were averaged for 
each gene in each sample.  The expression of each gene across the samples was compared 
by subtracting the largest average ∆CT for each gene from the other ∆CT gene values to 
determine the ∆∆CT for each sample tested for that specific gene.  The fold difference of 
relative gene expression was calculated for each gene sample using the formula 2-∆∆CT. 
 
Statistical Analysis 
 The ∆CT values for each sample tested within each gene were analyzed using the 
SPSS (Statistical Package for the Social Sciences; SPSS Inc, Chicago, IL).  Homogeneity 
of variance was confirmed using the Levene’s statistic with a P value of 0.05 for each 
gene data set followed by an ANOVA (Analysis of Variance) with a P value significance 
level of 0.05.  Following a determination of significant difference of relative gene 
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expression levels with the ANOVA, Tukey’s honestly significance difference (Tukey’s 
HSD) multiple comparison test was performed with a P value of 0.05 to determine 
specifically which changes in gene expression were significant.
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Table 3.1:  Primer Sequences Used in Confirmation PCR Reactions.   
    
Clone Number: Primer Sequences: Ta: (oC) 
Product 
Size: (bp) 
  
  
129-1-C1 5' - CGTGAATCGGGGGACCTTG - 3' 58.0 503 
 5' - CCCGACGGCATCTTTATTACACAG - 3'   
129-1-C3 5'- CTGGCGAAAGGGGGATGTG -3' 56.3 488 
 5' - GCAGTAACAGCAAGGGTGAAAAG - 3'   
129-1-C4 5' - CGGGCCTCTTCGCTATTACG - 3' 57.5 488 
 5' - ACCCCCTCCTCTCAGTCTCCATC - 3'   
129-1-C6 5' - GGCGGCCAAGCAGTTCATAG - 3' 57.9 568 
 5' - CAGCCCCAGCACAGGACAAC - 3'   
129-1-C7 5' - GCCCCTTAGCTGACCTCTGG - 3' 55.9 397 
 5' - GCTTCCGGCTCGTATGTTGTG - 3'   
129-2-C11 5' - CGGGCCTCTTCGCTATTACG - 3' 58.5 592 
 5' - GCTTTTGCCCTTCTGCTCCAC - 3'   
B5A-C2 5' - CGGGCCTCTTCGCTATTACG - 3' 58.4 591 
 5' - GACACCCCAGAAGAGGACATCAG - 3'   
B5B-C8 5' - CAGGGAAATAACTTGAGATGACGGC - 3' 54.0 317 
 5' - GTGGGAGGTGGCTGAGGATGG - 3'   
B5B-C10 5' - CATGACACTACGTTGTTGCTGAGG - 3' 53.6 304 
 5' - GTTGGATTGGGATTTGAACTGGAG - 3'   
B5B-C12 5' - CGCCATCGGAGAGCATCAG - 3' 60.1 353 
 5' - TGGGGGAGGGTTCATCAATC - 3'   
B5B-C13 5' - CCCTCCTGTATGTTTTCGTCTTGC - 3' 57.3 416 
 5' - CGTTTGCCCGGCCCACTCTC - 3'   
B5B-C14 5' - TTAAGCTCCATAGGGTCTTCTCGTC - 3' 54.5 280 
 5' - GATAAAAGGAACTCGGCAAACAAG - 3'   
B5B-C15 5' - GACCCCAAGACATGTGAGCAACTG - 3' 56.3 581 
 5' - GACCAAAACCGCCTGACACCTG - 3'   
B5B-C16 5' - CTAGGGAGGCACAGCAATCACTTC - 3' 55.9 496 
 5' - TGAGGCCAGGCACCAAGG - 3'   
B5B-C17 5' - CTGGCAAACAGGACTGAGGTAGC - 3' 55.2 496 
 5' - GTGTGGAATTGTGAGCGGATAAC - 3'   
B5B-C18 5' - CACAGAGCGGCCAACGGG - 3' 56.1 535 
 5' - GGGCGACCTCTTCCTGCG - 3'   
F1-C1 5' - CATTTTCAGGGGACAGACAGACTTG - 3' 55.6 512 
 5' - CCGACGAACCCTCCAGAATAG - 3'   
F1-C2 5' - CCCGTTCTTTGGTTTATTGTTCAG - 3' 54.1 194 
 5' - CTCCATAATTATAAGAGCCGTTGTGC - 3'   
F1-C4 5' - CTATAATCATGGCCCGAGGACTTC - 3' 52.6 274 
 5' - CGTGTGTGTGAGGGTTGGAGG - 3'   
F1-C5 5' - CTGTGCAATGAATAGTTTAAAAATCTCTG - 3' 52.1 269 
 5' - GATCTGGCCATAGGATAAAGGATACC - 3'   
F1-C6 5' - GTTGGGGGAGGTGATGACTTG - 3' 55.7 287 
 5' - ACAGCGGGAAGGATGGAAAC - 3'   
T - C1 5' - GGCCCACTTAGATATTGATTTGTTG - 3' 51.6 204 
 5' - GGGTTGCCATTTCCTTCTCCAG - 3'   
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Table 3.2:  Primer Sequences Used in Real Time PCR reactions.   
    
Gene: Primers: Ta: ( oC) 
Product 
Size: (bp) 
    
Prdx1 5' - TGAATACAAAGGAAAATATGTTGTGTTCTTC - 3' 52.8 175 
 5' - TGTGTTAATCCATGCCAGATGACA - 3'   
Vdacs 5' - ATTTGTACCAAACACAGGAAAGAAGAG - 3' 54.7 267 
 5' - CCAAACTCAGTGCCATCATTCAC - 3'   
Ywhaz 5' - CATCTGCAACGATGTACTGTCTCTT - 3' 53.2 161 
 5' - GTGACTGGTCCACAATTCCTTTC - 3'   
r18s 5' - TCAAGAACGAAAGTCGGAGGTT - 3' 61.0 488 
 5' - GGACATCTAAGGGCATCACAG - 3'   
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CHAPTER IV 
 
 
FINDINGS 
Sample cDNA Synthesis 
Blastocyst and Trophectoderm 
 The blastocyst and trophectoderm samples both began the suppression subtraction 
hybridization (SSH) process with the Super SMARTTM PCR cDNA Synthesis Kit which 
allows for starting total RNA concentrations of 10 ng to 1000 ng.  Each of the 5 
blastocyst samples began with 232.4 ng of total RNA while the trophectoderm sample 
began with 301.5 ng.   
 Following the 33 PCR cycles of the second strand synthesis optimization 
protocol, cDNA products were observed on the agarose gels for the blastocysts and 
trophectoderm ranging from .4 kb to over 4 kb (Figure 4.1 – blastocyst gel).  The gels 
revealed the optimum number of PCR cycles for the blastocyst to be 23 while the 
trophectoderm sample required 27 cycles.   The optimum number of cycles was one cycle 
less than the number required to reach plateau amplification. 
   Once the cDNA products were amplified, they were purified by column 
chromatography.  Subsequent agarose gel electrophoresis analysis revealed that both the 
first and the second elution fractions contained a significant portion of the cDNA samples 
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for both the blastocyst and trophectoderm samples, so for each sample, the two elution 
fractions were combined for the rest of the experiment (data not shown). 
 Following the Rsa I digestion and purification of the blastocyst and 
trophectoderm cDNA samples, UV spectrophotometry was used for sample 
quantification.  All samples ranged from 2-4 ug of cDNA which was within the expected 
quantities of 2-6 ug.  Several of the blastocysts samples had higher concentrations than 
what was allowed for adaptor ligation (300 ng/µl) so each was diluted to the allowable 
concentration.  The trophectoderm was slightly below this concentration (~297 ng/µl) and 
therefore was not diluted. 
 
Stem Cells and Feeder Cells 
 The 129 SvEv stem cells and fibroblast feeder cells began the SSH process with 
the PCR-Select cDNA Subtraction Kit due to their increased number of available cells.  
Following the cDNA synthesis, purification, and Rsa I digestion, the products were 
analyzed by agarose gel electrophoresis.  As in the blastocyst and trophectoderm samples, 
cDNA products ranged from .4 kb to over 4 kb (data not shown). 
 
Suppression Subtraction Hybridization 
 For each of the samples being compared in SSH, Adaptor 1 and Adaptor 2R were 
ligated to aliquots of the tester sample.  To confirm ligation success, a ligation efficiency 
PCR was performed using two different sets of primers.  One set of primers was specific 
for the G3PDH housekeeping gene and produced an amplicon approximately 500 bp 
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(base pairs).  The second set of primers contained one primer for the 3’ end of the 
G3PDH gene and a second primer that is specific for the adaptor region that produced a 
band approximately 1.2 kb.  A sample gel is shown for the blastocyst versus blastocyst 
comparison in Figure 4.2.   
 The final control reaction of the SSH procedure was a PCR of the G3PDH 
housekeeping gene in the subtracted and the unsubtracted tester samples of each 
comparison.  Samples were pulled from each of the reaction tubes every 5 PCR cycles 
from cycle 18 through cycle 33 and analyzed on an agarose gel.  The G3PDH product 
appeared in the unsubtracted samples 5-10 cycles before it appeared in the subtracted 
samples giving evidence that the gene levels were indeed decreased in the subtracted 
sample (Figure 4.3). 
 For each pair of comparisons, a final agarose gel was run showing the amplified 
subtracted product from the secondary PCR reaction and the control unsubtracted 
product.  For the blastocysts versus blastocyst control comparison, a single discrete band 
was visible in the subtracted lanes as compared to general product smearing in the 
unsubtracted lanes (Figure 4.4).  In the trophectoderm and blastocyst comparison, both 
the forward and reverse subtractions showed a general decrease of product in comparison 
to the unsubtracted products, however both subtracted samples showed a general 
smearing of numerous products rather than a limited number of discrete product bands 
(Figure 4.5).  In the stem cell and blastocyst comparison, both subtracted products 
showed a decrease in product as compared to the unsubtracted samples, however the stem 
cell sample especially showed a substantial decrease in product bands (Figure 4.6).  In the 
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final comparison, stem cell and feeder cell, a significant decrease of product was also 
visible in the subtracted versus the unsubtracted lanes (Figure 4.7). 
 
Cloning and Sequencing of Subtracted cDNA 
From the amplified subtracted products, approximately 300 clones were selected 
for analysis.  Since the blastocyst versus the stem cell comparison was of the greatest 
interest, most of the clones came from this comparison, however some clones came from 
all comparisons except for the blastocyst versus blastocyst comparison.  From those 300 
analyzed clones, 44 clones were sent for sequencing to the OSU Core Facility.  Of the 
sequenced clones, 8 were from pBluescript II SK+ and the remaining 36 were from 
pCR4-TOPO.  The obtained sequences were compared to known sequences in the NCBI 
GenBank through a BLAST search.  Of the sequenced clones, 11 contained only 
plasmids, 7 of which were pBluescript II SK+ and 4 were pCR4-TOPO.  From the 
remaining 33 sequences, 10 were of ribosomal origin while the other 23 were of a gene 
specific origin or else unknown.  Table 4.1 summarizes the clone sequences for those 
other than plasmid only. 
 
Confirmation Through PCR 
 For the 22 sequences that were of non-ribosomal origin, primers were designed 
and confirmation PCR reactions were run.  All PCR products were examined by agarose 
gel electrophoresis. 
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 In general, the agarose gels could be visually examined to see evidence of the 
differential expression of the genes by comparison of the intensity of the PCR product 
between the two samples.  An example of this can be seen in the gel picture for clone 
129-1-C1 (Figure 4.8).  In a few gels however, such as for F1-C4 and F1-C6, the bands 
appeared visually equal and the differential expression was not visually evident (data not 
shown).  In other gels, such as B5B-C12, the differential expression was very evident by 
band intensity, however faint additional bands were evident, giving evidence of the need 
to optimize the PCR reaction (Figure 4.9).   
 Since the confirmation PCRs were not quantitative, the research progressed to the 
real time PCR reactions for quantitative results.  However, based on the evidence of 
differential expression in the confirmation PCR reactions in combination with the identity 
of the clones based on the GenBank search (Table 4.1), three genes of interest were 
selected for the subsequent reactions. 
 
Quantification with the Real Time Polymerase Chain Reaction 
 The gene expression levels of Prdx1, Ywhaz, and Vdacs3 were quantified in 
comparison to r18s through the real time polymerase chain reaction using the DyNAmo 
HS SYBR Green qPCR Kit (Finnzymes) in the DNA Engine Opticon 2 (MJ Research) 
(Figures 4.10 – 4.13).   Each gene was tested twice in two different reactions for a total of 
four data sets for each gene in each sample.  Melting curve analysis was also performed 
for each amplification run to ensure purity of amplification product since the DyNAmo 
HS SYBR Green binds to any double-stranded DNA product and is not gene specific 
(Figures 4.14 – 4.17).   
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The ribosomal 18s CT values varied across the four different test samples from 
11.85 to 22.21 with the highest in the blastocyst sample.  It was expected however that 
the r18s value would be the highest within the blastocyst sample due to the high 
transcriptional activity associated with development.  The real time PCR CT value and 
fold difference calculation values can be seen in Table 4.2.   
 For the gene Prdx1, the lowest level of expression was seen in the feeder cells as 
expected with the levels of expression in the two stem cell samples surpassing that of the 
blastocyst sample.  The great variation however between fold differences for the two 
stem cell samples however was an interesting note as the 129 SvEv stem cells had a 7.51 
fold difference of expression and the C57BL/6 stem cells had a calculated 27.28 fold 
difference (Figure 4.18). 
 In the Ywhaz gene samples, the feeder cells once again expressed the lowest 
levels of transcript, however the blastocyst sample had a higher fold difference (7.65) of 
expression than the 129 SvEv stem cells (6.49) but lower level than the C57BL/6 stem 
cells (16.56) (Figure 4.19). 
 The blastocyst sample expressed the lowest level of the final gene, Vdacs3, 
followed by the feeder cells (2.16).  The stem cells had a much higher level of fold 
difference of expression as seen in the 129 SvEv stem cell calculation of 68.07 and 
C57BL/6 stem cell value of 161.04 (Figure 4.20). 
 
Statistical Analysis 
 The ∆CT values for each sample within each gene were analyzed for statistical 
differences.  Levene’s Test of Homogeneity (Table 4.3) first confirmed that the group 
 65 
variances were equal based on p = 0.05 in order to allow further testing by an ANOVA.  
An ANOVA for each gene confirmed that differences did exist within each comparison 
with a significance level at p = 0.05 (Table 4.4).   
 Tukey’s HSD analysis was used to confirm the specific significant differences 
within each gene group with p=0.05 (Table 4.5).  The data was also analyzed with the 
Least Significant Difference (LSD) multiple comparison test (data not shown) which 
showed a greater number of significant comparisons however since this test is not as 
stringent as Tukey’s HSD and not as widely accepted, presented significance was based 
only on the Tukey’s HSD results. 
 For Prdx1, the blastocyst sample was significantly different from the C57BL/6 
stem cells at a significance of p = 0.034.  In addition, the feeder cells were significantly 
different from the 129 SvEv stem cells (p = 0.014) and the C57BL/6 stem cells (p = 
0.000).  In the Ywhaz sample, the 129 SvEv stem cells and C57BL/6 stem cells showed 
significant differences at p = 0.045.  The feeder cells also showed significant differences 
from all other samples (p = 0.000 for all). 
 The final sample, Vdacs3, showed four significant differences, all at a p = 0.000 
value.  The first two were between the blastocyst sample and each of the stem cell 
samples, 129 SvEv and C57BL/6.  The second two significant differences existed 
between the feeder cells and the two stem cell samples. 
 In summary, the feeder cells showed significantly lower expression of each of 
these genes from either of the stem cell samples, therefore allowing that any significant 
differences between the stem cells and the blastocyst sample can be attributed more to the 
stem cells expression levels and not to any unavoidable feeder cell contamination.  When 
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comparing the stem cell samples, they showed significant differences of expression for 
the Ywhaz gene but not Prdx1 or Vdacs3.  For the blastocyst sample, it showed 
significant differences from the C57BL/6 stem cells for Prdx1 and from both stem cell 
samples for Vdacs3.   
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Figure 4.1 PCR Optimization of Blastocyst Sample.  Aliquots were pulled from a PCR 
reaction of a blastocyst sample, every three cycles from cycle 15 through cycle 33 (Lanes 
2-8) and analyzed by agarose gel electrophoresis.  The optimum number of cycles was 
determined to be one cycle less than the number required to reach plateau amplification.  
The optimum number of cycles was determined to be 23.  Lane 1 has a 1 KB+ ladder.   
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Figure 4.2 Ligation Efficiency PCR for Blastocyst vs. Blastocyst.   For each sample 
tested by SSH, a ligation efficiency PCR was done with primers for the G3PDH gene 
producing a 500 bp amplicon and an approximately 1.2 kb adaptor region amplicon.  This 
gel shows the bands after 25 cycles as per the kit protocol but due to the faint appearance, 
the PCR was extended for another 7 cycles and analyzed by gel electrophoresis a second 
time which showed the bands with greater intensity but also some non-specific smearing 
due to over-amplification.  The product visible on the graph verifies that sufficient 
adaptor ligation has occurred for the experiment to continue with adequate subtraction 
efficiency.  
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Figure 4.3 Subtraction Efficiency PCR for Blastocyst vs. Blastocyst.  For each SSH 
comparison, a final control PCR amplified the G3PDH gene in both the subtracted and 
the control unsubtracted sample.  In each PCR, samples were pulled at cycles 18, 25, 28, 
and 33 for analysis by agarose gel electrophoresis.  The left side of the gel shows the 
samples for the subtracted followed by the unsubtracted samples for the first blastocyst 
sample and the right side has the same layout for the second blastocyst sample. The four 
lanes of ladder are all 1 KB+ ladder.  For the first blastocyst sample, the first faint 
product band appears after 25 cycles in the subtracted product, but for the unsubtracted 
control, a significant band is apparent after 18 cycles.  For the second blastocyst sample 
(right), the first faint band appears after 28 cycles for the subtracted sample but once 
again has a dark band in the unsubtracted control after 18 cycles.  These results confirm 
that the gene levels were indeed decreased in the subtracted products through SSH. 
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Figure 4.4 Blastocyst vs. Blastocyst Secondary Subtraction PCR Product.  For each 
pair of comparisons, the amplified subtracted product from the secondary PCR reaction 
and the control unsubtracted product were analyzed by agarose gel electrophoresis.  The 
lanes are as follows: 1 – 1 KB+ ladder, 2 – subtracted blastocyst sample 1, 3- control 
unsubtracted blastocyst sample 1, 4 – subtracted blastocyst sample 2, 5 – control 
unsubtracted blastocyst sample 2, 6 – control subtracted human skeletal muscle sample, 7 
– control unsubtracted human skeletal muscle sample, and 8 – kit control subtracted 
product.  From the subtracted lanes, a single discrete band is visible as compared to the 
general product smearing seen in the unsubtracted lanes. 
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Figure 4.5 Trophectoderm vs. Blastocyst Secondary Subtraction PCR Product.  For 
each pair of comparisons, the amplified subtracted product from the secondary PCR 
reaction and the control unsubtracted product were analyzed by agarose gel 
electrophoresis.  The lanes are as follows: 1 – 1 KB+ ladder, 2 – subtracted 
trophectoderm sample, 3- control unsubtracted trophectoderm sample, 4 – subtracted 
blastocyst sample, 5 – control unsubtracted blastocyst sample, 6 – control subtracted 
human skeletal muscle sample, 7 – control unsubtracted human skeletal muscle sample, 8 
– kit control subtracted product, and 9 – 1 KB+ ladder.  Both the forward and reverse 
subtraction samples show a general decrease of product in comparison to the 
unsubtracted product, however they still show a general smearing of numerous products 
rather than a limited number of discrete product bands. 
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Figure 4.6 129SvEv Stem Cell vs. Blastocyst Secondary Subtraction PCR Product.  
For each pair of comparisons, the amplified subtracted product from the secondary PCR 
reaction and the control unsubtracted product were analyzed by agarose gel 
electrophoresis.  The lanes are as follows: 1 – 1 KB+ ladder, 2 – subtracted blastocyst 
sample, 3- control unsubtracted blastocyst sample, 4 – subtracted stem cells sample, 5 – 
control unsubtracted stem cell sample, 6 – control subtracted human placenta sample, 7 – 
control unsubtracted human placenta sample, 8 – control subtracted human skeletal 
muscle sample, and 9 – control unsubtracted human skeletal muscle sample.  Both the 
forward and reverse subtraction samples show a general decrease in number of transcript 
products in comparison to the unsubtracted product; however the stem cell sample 
showed a substantial decrease of product. 
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Figure 4.7 129SvEv Stem Cell vs. Fibroblast Feeder Cells Secondary Subtraction 
PCR Product.  For each pair of comparisons, the amplified subtracted product from the 
secondary PCR reaction and the control unsubtracted product were analyzed by agarose 
gel electrophoresis.  The lanes are as follows: 1 – 1 KB+ ladder, 2 – subtracted stem cells 
sample, 3 – control unsubtracted stem cell sample, 4 – subtracted fibroblast sample, 5- 
control unsubtracted fibroblast sample, 6 – control subtracted human skeletal muscle 
sample, 7 – control unsubtracted human skeletal muscle sample, and 8 – kit control 
subtracted product.  All of the subtracted samples showed a visible decrease in product. 
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Figure 4.8 Confirmation PCR of Clone 129-1-C1.  DNA sequences identified as 
differentially expressed through Suppression Subtraction Hybridization and isolated for 
cloning were visually confirmed as differentially expressed through PCR in the original 
samples used for comparison.  The lanes are as follows: 1 – 1 KB+ ladder, 2 – 129SvEv 
Stem Cells, 3 – Fibroblast Feeder Cells, 4 – C57BL/6 Stem Cells, and 5 – Negative 
Control.  An increase in product is visible in both stem cell samples as in comparison to 
the fibroblast sample, confirming the results of the SSH. 
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Figure 4.9 Confirmation PCR of Clone B5B-C12.  DNA sequences identified as 
differentially expressed through Suppression Subtraction Hybridization and isolated for 
cloning were visually confirmed as differentially expressed through PCR in the original 
samples.  The lanes are as follows: 1 – 1 KB+ ladder, 2 – Blank, 3 – 129 SvEv Stem 
Cells, 4 – Blastocyst, 5 – C57BL/6 Stem Cells, and 6 – Negative Control.  The stem cell 
samples show a greater yield of product than the blastocyst sample, however a number of 
non-specific bands are also visible in the 129SvEv stem cell sample indicating a need to 
optimize the PCR reaction. 
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Table 4.1:  GenBank Identities of Sequenced Clones  
 
 
 
  
Source: Identity:   Clone Number: 
GenBank 
Accession 
Numbers for 
Matches: 
Ribosomal 
 
129-2-C11 BK000964 
 
 
129-2-C12  Blastocyst vs Stem Cell  (B5B vs.129-2) 
 
 
129-2-C13  
 
 
 
129-2-C37  
 
 
 
129-2-C38  
 
 
 
129-2-C39  
 
 
 
129-2-C40  
 
 
 
129-2-C41  
 
  
  
B5B-C12 BC021595 
 
Tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase 
activation protein, zeta 
polypeptide (Ywhaz) 
  
B5B-C8 BC05089    
NM_011740 
 
Voltage-dependent anion 
channel 3 (Vdacs3) 
  
B5B-C10 BC004743 
MMU30839 
NM_011696 
 
Mitochondrial 
  
B5B-C14 AY339599 
 
Glucose related protein 78/ 
Heat shock 70kD protein 5 
  
B5B-C15 MUSGRP78A 
BC050927 
MUSGRP784      
D78645 
 
GM2 activator protein 
(Gm2a) 
  
B5B-C16 NM_010299 
BC004651 
MMU09816 
 
Ribonucleotide reductase 
M2 (Rrm2) 
  
B5B-C17 NM_009104 
MUSRNRM2A 
 
Peroxiredoxin1 (Prdx1) 
  
B5B-C18                 
B5B-C19 
AK008711 
AK083243 
AK010688 
NM_011034 
  
RP515 Protein 
  
B5B-C13 AK010652 
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Trophectoderm vs. 
Blastocysts (T vs 
B5A) 
Unknown 
  
T1-C1   
  
Cleavage and 
polyadenylation specificity 
factor 3 (Cpsf3) 
  
B5A-C2 BC006748, 
XW_358148, 
BC023297, 
NM_018813, 
AK045238,  
AK010566,   
AK004317 
Stem Cell vs. Feeder 
Cell (129-1 vs. F1) 
Proliferating cell nuclear 
antigen 
  
129-1-C1              
129-1-C2 
BC005778 
 
Unknown 
 
129-1-C3  
 
 
 
129-1-C7  
 
  
  
F1-C5   
 
mKIAA1430 
protein/4933411K20 gene 
 
129-1-C4             
129-1-C5 
AK129358, 
BC058092, 
NM_025747 
 
Ribosomal 
  
129-1-C6 AK088777 
 
Thromospondin 1 
  
F1-C1 BC042422 
 
Cyclin G1 
  
F1-C2 BC005534 
 
S100 calcium binding 
protein A11 (calizzarin) 
 
F1-C3                       
F1-C6 
BC021916, 
NM_016740 
 
Mitochondrial 
  
F1-C4 BC020382 
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Figure 4.10 Real Time PCR Amplification Graph for Ribosomal 18s, Run 1.  The 
graph demonstrates the amount of replicated r18s product with each amplification cycle 
in each of the three samples, murine blastocyst, 129SvEv murine embryonic stem cells, 
and C57Bl/6 murine embryonic stem cells, as determined by DyNAmo HS SYBR Green 
fluorescence.  Each sample was tested twice in each run.  Each run was repeated a second 
time for a total of four data sets for each gene in each sample.  The second amplification 
graph for this gene is comparable to this graph and is not shown. 
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Figure 4.11 Real Time PCR Amplification Graph for Prdx1, Run 1.  The graph 
demonstrates the amount of replicated Prdx1 product with each amplification cycle in 
each of the three samples, murine blastocyst, 129SvEv murine embryonic stem cells, and 
C57Bl/6 murine embryonic stem cells, as determined by DyNAmo HS SYBR Green 
fluorescence.  Each sample was tested twice in each run.  Each run was repeated a second 
time for a total of four data sets for each gene in each sample.  The second amplification 
graph for this gene is comparable to this graph and is not shown. 
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Figure 4.12 Real Time PCR Amplification Graph for Ywhaz, Run 1.  The graph 
demonstrates the amount of replicated Ywhaz product with each amplification cycle in 
each of the three samples, murine blastocyst, 129SvEv murine embryonic stem cells, and 
C57Bl/6 murine embryonic stem cells, as determined by DyNAmo HS SYBR Green 
fluorescence.  Each sample was tested twice in each run.  Each run was repeated a second 
time for a total of four data sets for each gene in each sample.  The second amplification 
graph for this gene is comparable to this graph and is not shown. 
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Figure 4.13 Real Time PCR Amplification Graph for Vdac3, Run 1.  The graph 
demonstrates the amount of replicated Vdac3 product with each amplification cycle in 
each of the three samples, murine blastocyst, 129SvEv murine embryonic stem cells, and 
C57Bl/6 murine embryonic stem cells, as determined by DyNAmo HS SYBR Green 
fluorescence.  Each sample was tested twice in each run.  Each run was repeated a second 
time for a total of four data sets for each gene in each sample.  The second amplification 
graph for this gene is comparable to this graph and is not shown. 
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Figure 4.14 Melting Curve Analysis for Ribosomal 18s Amplification, Run 1.  A 
melting curve analysis was done for each real time PCR run from 50oC to 90oC.  The 
graph is of the rate of change of relative fluorescence with time and therefore peaks at the 
melting temperature of the product.  This graph demonstrates a uniform peaking at the 
r18s melting point (84.4 oC) for all samples and confirms that fluorescence reading within 
those wells were only due to the presence of the desired amplicon and not primer dimers 
or random priming products.  The melting curve for the second run is comparable to this 
graph and therefore is not shown. 
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Figure 4.15 Melting Curve Analysis for Prdx1 Amplification, Run 1.  A melting 
curve analysis was done for each real time PCR run from 50oC to 90oC.  The graph is of 
the rate of change of relative fluorescence with time and therefore peaks at the melting 
temperature of the product.  This graph demonstrates a uniform peaking at the Prdx1 
melting point (78.8 oC) for all samples and confirms that fluorescence reading within 
those wells were only due to the presence of the desired amplicon and not primer dimers 
or random priming products.  The melting curve for the second run is comparable to this 
graph and therefore is not shown. 
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Figure 4.16 Melting Curve Analysis for Ywhaz Amplification, Run 1.  A melting 
curve analysis was done for each real time PCR run from 50oC to 90oC.  The graph is of 
the rate of change of relative fluorescence with time and therefore peaks at the melting 
temperature of the product.  This graph demonstrates a uniform peaking at the Ywhaz 
melting point (79.6 oC) for all samples and confirms that fluorescence reading within 
those wells were only due to the presence of the desired amplicon and not primer dimers 
or random priming products.  The melting curve for the second run is comparable to this 
graph and therefore is not shown. 
 85 
 
 
 
 
Figure 4.17 Melting Curve Analysis for Vdac3 Amplification, Run 1.  A melting 
curve analysis was done for each real time PCR run from 50oC to 90oC.  The graph is of 
the rate of change of relative fluorescence with time and therefore peaks at the melting 
temperature of the product.  This graph demonstrates a uniform peaking at the Vdac3 
melting point (81.6 oC) for all samples and confirms that fluorescence reading within 
those wells were only due to the presence of the desired amplicon and not primer dimers 
or random priming products.  The melting curve for the second run is comparable to this 
graph and therefore is not shown. 
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Table 4.2:  Real Time PCR Fold Difference Calculations. 
 
 
Gene: Samples: Sample Avg. CT†: 
r18s Avg. 
CT†: 
∆CT‡: ∆∆ CT§: Fold Difference¶: 
Prdx1 Blastocyst  24.83 ± 1.41 22.21 ± 0.63 2.62 -2.27 4.81 
  129 SvEv SC 13.83 ± 1.31 11.85 ± 0.29 1.98 -2.91 7.51 
  C57BL/6 SC 12.91 ± 0.59 12.79 ± 0.87 0.12 -4.77 27.28 
  Feeder Cells 18.21 ± 0.83 13.32 ± 0.26 4.89 0.00 1.00 
Ywhaz Blastocyst 23.13 ± 0.65 22.21 ± 0.63 0.92 -2.94 7.65 
  129 SvEv SC 13.00 ± 0.61 11.85 ± 0.29 1.15 -2.70 6.49 
  C57BL/6 SC 12.59 ± 0.77 12.79 ± 0.87 -0.20 -4.05 16.56 
  Feeder Cells 17.17 ± 0.47 13.32 ± 0.26 3.85 0.00 1.00 
Vdacs3 Blastocyst  29.52 ± 1.33 22.21 ± 0.63 7.31 0.00 1.00 
  129 SvEv SC 13.07 ± 0.63 11.85 ± 0.29 1.22 -6.09 68.07 
  C57BL/6 SC 12.77 ± 0.84 12.79 ± 0.87 -0.02 -7.33 161.04 
  Feeder Cells 19.52 ± 0.77 13.32 ± 0.26 6.20 -1.11 2.16 
 
Each average CT value is from a total of 4 data points obtained from two runs with 
duplicates in each run. 
 
† CT = Cycle Threshold; Cycle number in which product amplification fluorescence 
reaches a set threshold. (Threshold is set to the beginning of the exponential amplification 
phase of the product.) 
 
‡ 
∆CT = Sample Avg. CT – r18s Avg. CT; Normalization in regards to the reference gene. 
 
§ 
∆∆CT = The largest ∆CT from the data set for each gene is subtracted from the 
remaining ∆CT values.  The sample with the largest ∆CT has the lowest target expression 
and is subtracted from all other samples. 
 
¶ Fold Difference is calculated using 2 -∆∆CT; Fold difference normalized to the reference 
gene and relative to the gene with the lowest expression. 
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Figure 4.18 Fold Differences in Prdx1 Gene Expression Levels Based on Real Time 
PCR.  Notations a-c indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For a, p = 0.034, for b, p = 0.014, and 
for c, p = 0.000. 
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Figure 4.19 Fold Differences in Ywhaz Gene Expression Levels Based on Real Time 
PCR.  Notations a-d indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For a, p = 0.045, for b, p = 0.000, for c, 
p = 0.000, and for d, p = 0.000. 
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Figure 4.20 Fold Differences in Vdacs3 Gene Expression Levels Based on Real Time 
PCR.  Notations a-d indicate statistically significant comparisons as identified by 
Tukey’s honestly significant difference analysis.  For all four comparisons,  p = 0.000 
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Table 4.3:  Levene's Test of Homogeneity of Variance for Quantitative PCR ∆CT 
Values 
 
Gene: Significance: 
Prdx 1 0.267 
Ywhaz 0.715 
Vdacs3 0.454 
 
 
 
 
 
 
Table 4.4:  ANOVA for Quantitative PCR ∆CT Values.  Comparison of the ∆CT values 
for each sample within each gene analysis to look for statistical differences.  ANOVA 
confirmed there were differences in the relative expression levels for all three genes 
between the 4 samples. 
 
 
Gene: Significance: 
Prdx 1 0.001 
Ywhaz 0.000 
Vdacs3 0.000 
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Table 4.5:  Tukey's HSD for Quantitative PCR ∆CT Values 
 
Gene: Test Sample: Test Sample: Significance:  
Prdx 1 Blastocyst 129 SvEv ESC 0.843  
    C57BL/6 ESC 0.034 * 
    Feeder Cells 0.058  
  129 Stem Cells  Blastocyst 0.843  
    C57BL/6 ESC 0.137  
    Feeder Cells 0.014 * 
  C57 Stem Cells Blastocyst 0.034 * 
    129 SvEv ESC 0.137  
    Feeder Cells 0.000 * 
  Feeder Cells Blastocyst 0.058  
    129 SvEv ESC 0.014 * 
    C57BL/6 ESC 0.000 * 
Ywhaz Blastocyst 129 SvEv ESC 0.950  
    C57BL/6 ESC 0.112  
    Feeder Cells 0.000 * 
  129 Stem Cells  Blastocyst 0.950  
    C57BL/6 ESC 0.045 * 
    Feeder Cells 0.000 * 
  C57 Stem Cells Blastocyst 0.112  
    129 SvEv ESC 0.045 * 
    Feeder Cells 0.000 * 
  Feeder Cells Blastocyst 0.000 * 
    129 SvEv ESC 0.000 * 
    C57BL/6 ESC 0.000 * 
Vdacs3 Blastocyst 129 SvEv ESC 0.000 * 
    C57BL/6 ESC 0.000 * 
    Feeder Cells 0.371  
  129 Stem Cells  Blastocyst 0.000 * 
    C57BL/6 ESC 0.282  
    Feeder Cells 0.000 * 
  C57 Stem Cells Blastocyst 0.000 * 
    129 SvEv ESC 0.282  
    Feeder Cells 0.000 * 
  Feeder Cells Blastocyst 0.371  
    129 SvEv ESC 0.000 * 
    C57BL/6 ESC 0.000 * 
* The mean difference is significant at the 0.05 level.  
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CHAPTER V 
CONCLUSION 
 Potential applications of embryonic stem cells have been greatly discussed from 
advances in knowledge about embryonic development, to drug development and repair of 
damaged tissue.  However, while a great amount of research has gone into understanding 
general stem cell characteristics, limited work had been done to characterize the 
developmental progression of embryonic stem cells from the blastocyst stage embryo. 
 The primary focus of this research was to utilize suppression subtraction 
hybridization to characterize the transcriptional differences between murine blastocyst 
stage embryos and murine embryonic stem cells.  SSH was especially appropriate for this 
research due to its ability to begin with limited amounts of research material as well as its 
ability to amplify genes that are differentially expressed between two samples without 
prior gene specific knowledge. 
 From four SSH comparisons, blastocyst vs. blastocyst, trophectoderm vs. 
blastocyst, blastocyst vs. 129SvEv stem cells, and 129SvEv stem cells vs. fibroblast 
feeder cells, sequences were obtained for 33 clones of uniquely expressed transcripts.  
From this group, 10 clones were identified as having ribosomal homologies while 23 
clones had either gene specific homologies or else were unknown.  Three of the 23 genes, 
Prdx1, Ywahz, and Vdacs3, were selected for future quantitative analysis through
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real time PCR in blastocyst, 129SvEv stem cell, C57BL/6 stem cells, and fibroblast 
feeder cell samples. 
 
Peroxiredoxin 1 
 For Prdx1, in comparison to the fibroblast feeder cells which had the lowest 
expression level, the blastocyst had a 4.81 fold expression level difference, the 129SvEv 
stem cells had a 7.51 fold difference, and the C57BL/6 stem cells showed a 27.28 fold 
difference.  Expression levels were significantly different between the blastocyst and 
C57BL/6 samples as well as the fibroblast feeder cells and both stem cell samples based 
on statistical analysis of the ∆CT values.  The significant difference in expression levels 
between the stem cells and the fibroblast verifies that the high rate of expression 
demonstrated within stem cells was not a false result created by the possibility of 
fibroblast contamination through routine cell culture conditions at the time of stem cell 
collection.  
 
Peroxiredoxin 1 Overview 
Peroxiredoxin-1 (Prdx1) is a cytoplasmic protein belonging to the peroxiredoxin 
family (Prdxs) which includes antioxidant proteins in organisms from all three kingdoms.  
Prdx1 is ubiquitously distributed throughout various types of mammalian tissue and is 
coded for by chromosome 4 in the mouse, producing a protein with a relative molecular 
mass of 23 kDa [47, 48].  The peroxiredoxins protect the cells from reactive oxygen 
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species (ROS) such as hydrogen peroxide (H2O2) by reduction through the thioredoxin 
(TRX) system [49].   
Prdx1 exists within the cell as a homodimer consisting of two monomers arranged 
anti-parallel and is classified within the peroxiredoxin family based on its two conserved 
cysteine molecules, Cys52 and Cys173.  It functions to eliminate H2O2 by oxidizing a Cys52 
residue to form cysteine sulfenic acid (Cys-SOH) which subsequently reacts with the 
Cys173 residue of the other monomer (Figure 5.1).  This produces an intermolecular 
disulfide bond accompanied by the release of water.  The disulfide bond is subsequently 
reduced by thioredoxin [50, 51]. 
Several mechanisms for the regulation of Prdx1 have been discovered.  Prdx1 
contains a phosphorylation site utilized by cyclin-dependent kinases (Cdk) which results 
in a decrease in peroxidase activity.  Research of cells halted at varying stages of the cell 
cycle, demonstrated that Prdx1 was phosphorylated simultaneous to Cdc2 kinase 
activation [51].  In addition, nuclear factor (erythroid-derived-2)-related factor (Nrf2), 
has been shown to be an important transcription factor for Prdx1, especially in response 
to hypoxia and reoxygenation, a characteristic of a tumor microenvironment [50]. 
 
Peroxiredoxin 1 Cellular Implications 
The ROS have long been considered to be toxic by-products of cellular activity 
(metabolism, etc.) and environmental factors (radiation, drugs, etc.) with the potential to 
cause great harm to the cell such as oxidation of proteins, lipid peroxidation, and DNA 
modification or breakage.  Research has shown that mutant mice lacking the Prdx1 gene 
and therefore less able to eliminate ROS, develop hemolytic anemia and malignant 
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cancers resulting in shortened lifespans.  The loss of Prdx1 expression in heterozygotes 
similarly saw an increase in these lymphomas, sarcomas, and carcinomas which also 
indicates a potential role for the protein in tumor suppression [47].  
Other research however has linked ROS to a wider range of cellular regulatory 
activities in mammalian cells.  For example, nitric oxide aids in immune system response 
in effector cells, such as the macrophages, when produced at high levels, but at lower 
levels is believed to function in signal transduction in a variety of cell types [51, 52].  
Similarly, ROS have been found to be involved in transcription regulation in bacteria [53] 
as well as signal transduction in plants [54].  Other studies have shown that when various 
types of cells are stimulated by a variety of ligands such as cytokines and peptide growth 
factors, the intracellular levels of ROS increase, suggesting a role as a second messenger 
molecule [52].  For example, it has been demonstrated that hydrogen peroxide oxidizes 
protein tyrosine phosphatases (PTP) in response to stimulation by growth factors, 
resulting in PTP inactivation [51, 55]. 
This more complex understanding of the role of ROS in cellular activity also 
indicates a more complex involvement of Prdx1 in signaling cascades and redox 
regulation of the cell [49].  Research has shown Prdx1 transcription to increase in human 
mammary epithelial cell lines induced to proliferate by serum stimulation with a decrease 
in expression in subsequent differentiation [56].    Similarly, through use of a cDNA 
expression array, Prdx1 was found to be down-regulated during differentiation of a 
human embryonal carcinoma cell line used as a model for human neuronal differentiation 
[57].   
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Additional research has also indicated a role for peroxiredoxin 1 in enhancing cell 
survival.  Prdx1 expression has been found to be upregulated in several types of cancer, 
including squamous cell lung carcinomas [50, 58] as well as in Alzheimer’s disease and 
Down Syndrome [59].  In addition, research on embryonic interdigital cell death found 
Prdx1 downregulated at the time of commitment to programmed cell death, however 
normal levels of Prdx1 were maintained when the cultures were induced to survive.  
Interestingly though, silencing of Prdx1 though RNA interference treatment, failed to 
cause interdigital death, therefore indicating the required involvement of additional 
cellular components [60]. 
Other research using a proteomic approach, however, has shown Prdx1 to be 
upregulated during differentiation of a human fetal midbrain cell line [61] as well in the 
rat striatal progenitor model cell line ST14A transfected with glial cell line-derived 
neurotrophic factor (GDNF), an important neuronal differentiation factor.  Interestingly, a 
Prdx1 expression change was not detected in untransfected ST14A within the 72 hours of 
the study [62].  Additionally, previous research by the group on a transcriptional level 
though use of microarrays, failed to reveal any differences in Prdx1 levels between 
transfected and untransfected ST14A cells [63]. 
Prdx1 has been shown to specifically interact with myelocytomatosis oncogene 
(c-Myc) , a transcription factor with roles in the cell cycle, differentiation, cell size, and 
apoptosis through its interaction with over 1000 different genes [64, 65].  Alterations in 
the expression of c-Myc have been documented in a large variety of cancers, including 
Burkitt’s lymphoma, and prostate, breast, and colon cancers. [65].  Recent research by 
Egler, et al. in embryonic fibroblasts taken from a mutant prdx1 -/- mouse strain, 
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demonstrated increased levels of ROS in addition to signs of the deregulation of c-Myc, 
including decreased growth rates and altered c-Myc target gene expressions [65].  This 
interaction by Prdx1 further support its role as a tumor suppressor gene in addition to its 
role in eliminating ROS [64, 65]. 
Prdx1 has also been demonstrated to associate in vivo and in vitro with Abelson 
leukemia oncogene (c-Abl), a tyrosine-kinase with reported roles in inhibiting cell 
division, cellular response to stress, cell adhesion, and differentiation.  c-Abl migrates 
between the cytoplasm and the nucleus and oxidative stress has been shown to activate c-
Abl.  Within the nucleus, c-Abl responds to DNA damage with apoptotic signaling [66].  
Overexpression of Prdx1 inhibited c-Abl kinase activity [67].  This inhibition can have a 
significant impact on abnormal cell development as one of the normal functions of c-Abl 
is protector of p53, a well-studied tumor suppressor gene, by interactions with p53’s 
inhibitors [68]. 
 
Peroxiredoxin 1 Research Significance 
Overall, recent research points to the fundamental role of Prdx1 as one of 
promoting cell survival within the stem cell samples.  As in the current research, a review 
of published supplemental data from research analyzing murine stem cells with 
microarrays also finds a high expression of Prdx1 within embryonic stem cells [69].  On 
the most basic level, Prdx1 protects cells from ROS and may play a role in various 
signaling cascades.  In addition, genomic studies show increased levels of Prdx1 during 
proliferation with decreasing levels during differentiation.  Conflicting proteomic studies 
indicating higher levels during differentiation still need to be resolved but may point to 
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alterations in the degradation rate of Prdx1.  Prdx1’s association with c-Myc and c-Abl, 
two molecules with roles in cell replication and apoptosis, as well as the experimental 
findings of Prdx1 being upregulated in various forms of cancer also support the role of 
Prdx1 as increasing cell survival and replication, essential characteristics for stem cells. 
 
Tyrosine 3-Monooxygenase/Tryptophan 5-Monooygenase Activation Protein 
 Similar to Prdx1, the fibroblast feeder sample also showed the lowest expression 
level of Ywhaz.  In comparison, the blastocyst sample showed a 7.65 fold difference of 
expression, the 129SvEv stem cells showed a 6.49 fold difference of expression, and the 
C57BL/6 stem cells showed a 16.56 fold difference of expression.  In analysis of the ∆CT 
values, the two stem cell sample values were significantly different from each other as 
was the fibroblast feeder cell value from all other samples; however the blastocyst sample 
was not significantly different from either stem cell sample. 
 
Ywhaz Overview 
 Tyrosine 3-monooxygenase/tryptophan 5-monooygenase activation protein, zeta 
polypeptide (Ywhaz), also known as 14-3-3 zeta (14-3-3 ζ), is one of seven mammalian 
isoforms of the highly conserved 14-3-3 protein family.  They were first described in 
1967 as copious proteins found in the bovine brain and named 14-3-3 based on their 
isolation pattern [70].  Although there are seven known isotypes, a search of the human 
genome indicates a potential of three additional homologous transcripts to be discovered 
[71].  While their largest concentration is within the brain (1% of soluble proteins), most 
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isoforms have also been detected in lower levels within numerous other tissues.   Despite 
specific knowledge about the roles of some mammalian isoforms, much of the functional 
differences between the various isoforms has yet to be determined [72].  As the expanded 
name would indicate, one of their first discovered roles, was as activators of tryptophan 
5-monooxygenase and tyrosine 3-monooxygenase, therefore involved in the regulation of 
serotonin and noradrenalin production in the brain [73].  In general however, they have 
been found to interact with hundreds of other proteins with roles in cell signaling, cell 
cycle regulation, transcription, apoptosis, cytoskeletal structure, metabolism, 
oncogenesis, and intracellular trafficking/targeting [70, 74-76].  Their general 
mechanisms of action include altering target protein activity, altering target proteins 
interactions with other proteins, altering protein modifications, preventing degradation, 
and intracellular localization of target proteins [77, 78]. 
 Ywhaz, like the other 14-3-3 proteins, consists of two 30 kDa acidic monomers, 
each with nine antiparallel α-helices organized with N-terminal and C-terminal domains, 
together forming a helical, dimeric protein with a large, negatively charged groove or 
channel (Figure 5.2).  Within the channel are conserved regions that are common among 
all 14-3-3 proteins while the exterior portion of the protein has isoforms specific 
variations which most likely account for the variation in ligand binding activities between 
the different isoforms.  In addition, conserved phosphorylation sites for each isoforms 
assist in the regulation of binding motifs.  The phosphorylated form of 14-3-3 ζ was 
originally discovered separately and given the name 14-3-3 δ (delta) [70].  In addition to 
their homodimer formation, 14-3-3 isoforms have also been found in various heterodimer 
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arrangements including the binding of 14-3-3 ζ monomers with 14-3-3 ε monomers [79, 
80]. 
 In more recent years, the ubiquitous expression of Ywhaz has made it known as a 
housekeeping gene and it has been studied as a reference gene for use in real time PCR.  
In evaluation of appropriate reference genes in studies of dolphin skin biopsies [81], 
human placental tissue [82], and bovine preimplantation embryos [83], Ywhaz was 
among the three most stable reference genes from those studied.  In another study 
however of prostate cancer tissue, Ywhaz rated only 10th for expression stability among 
the sixteen genes studied [84]. 
 Variations in Ywhaz expression, however, have been researched as potential 
sources for a number of diseases.  A single nucleotide polymorphism (SNP) for Ywhaz 
was examined in an association study for paranoid schizophrenia and was found to occur 
significantly higher in patients than in matched controls [85].  In addition, 14-3-3 proteins 
are known to bind to α-synuclein, and Ywhaz, along with several other isoforms, is found 
to colocalize with Lewy bodies in Parkinson’s disease [86].  Ywhaz expression is also 
found to peak during progression of chronic myeloid leukemia through the late chronic 
stage [87].  In Alzheimer’s disease, neurofibrillary tangles composed of abnormally 
phosphorylated microtubule associated tau proteins are a key neuropathological 
characteristic.  Ywhaz has been detected associated with tau within brain extracts and 
Ywhaz has been shown in vitro to stimulate tau’s phosphorylation [88].  In addition, 14-
3-3 proteins have been found in the cerebrospinal fluid in studies of over twenty-four 
different diseases [71]. 
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Ywhaz Cellular Implications 
One of the many actions of the 14-3-3 proteins, including Ywhaz, is binding to 
cruciform DNA.  Cruciform DNA has been shown to form in both eukaryotic and 
prokaryotic organisms where inverted repeat sequences under constraints such as 
supercoiling, form non-B-DNA conformation through the formation of intra-strand base 
pairs.  This transient cruciform formation has been shown to correlate with DNA 
replication and transcription and the 14-3-3 cruciform binding protein (CBP) activity is 
seen only in replicating cells.  It is hypothesized that when this structural change occurs 
at origins of replication, it serves in the recruitment of initiator proteins and regulation of 
DNA replication.  Hence, due to their CBP activity, 14-3-3 proteins are believed to be 
involved in regulating DNA replication [89]. 
 Ywhaz also binds to a number of proteins and phosphorylation of both Ywhaz 
and the target proteins mediate this interaction.  Most interactions depend on a target 
phosphorylated serine or threonine motif, RSXpSXP and RXXXpSXP (pS represents 
both phosphoserine and phosphothreonine) [77, 90].  For example, Ywhaz has been 
shown to bind to Raf proteins aiding in their activation [91].  The Raf proteins are a 
family of three serine/threonine kinases (A-Raf, B-Raf and C-Raf or Raf-1) that operate 
in a variety of cellular cascades.  Raf-1 is ubiquitously expressed and functions in a 
signaling cascade downstream of Ras (Ras/Raf/MEK/ERK).  For example, when the 
pathway is stimulated by the epidermal growth factor receptor, it leads to a variety of 
changes such as increased levels of anti-apoptotic proteins, Bcl2, and inhibition of Bad, a 
proapoptotic protein.  In addition, Raf1 operates independently of the MEK/ERK 
pathway to activate Bcl2, inhibit proapoptotic proteins ASK1 and MST2, and promote 
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cell cycle continuation and differentiation [92, 93].   Phosphorylation of Ywhaz on Thr-
233 by casein kinase Iα (CKIα) however, prevents its association with Raf-1 (also known 
as c-Raf) [91] as does in vitro treatment of Raf-1 by phosphatase [94].   
 Like many other target proteins, several proapoptotic proteins are also known to 
require phosphorylation for association with 14-3-3 proteins (including 14-3-3ζ), 
including Bad, FOXOa, cAbl, Yap, Nur77, and Bim.  Bax, another proapoptotic protein, 
however does not require phosphorylation.  These proteins have been shown to associate 
in the cytoplasm with the 14-3-3 proteins which maintains them in a sequestered, 
inactivated form away from the mitochondria and nucleus.  Phosphorylation, however, of 
the 14-3-3 proteins (at Ser 184 for 14-3-3ζ) by c-Jun NH2-terminal kinase (JNK) in 
response to DNA damage or dephosphorylation of the target proteins (minus Bax) cause 
their release and therefore results in apoptotic cellular signaling.  (Foxo, Yap, Nur77, and 
cAbl function in the nucleus and Bad, Bim and Bax function in the mitochondria for their 
respective roles in apoptosis.)  (Figure 5.3)  In fact, low levels of 14-3-3 increase a cell’s 
susceptibility to apoptotic signals and increased 14-3-3 levels makes a cell more resistant 
to apoptotic signaling [66, 72, 76, 95-98]. 
 In addition to the regulation of 14-3-3 through the JNK phosphorylation at S184 
previously described, additional kinases Sdk1 (Sphingosine-dependent kinase) and PKA 
type II (protein kinase A type II) have also been found to phosphorylate 14-3-3 at S58.  
This residue lies in the dimeric interface and its phosphorylation prevents dimeric 
formation.  While the monomeric 14-3-3 may still be able to bind to some target proteins 
with a lower affinity, it would not be able to produce the conformational changes needed 
for the activation of some target proteins.  In addition, a number of 14-3-3 target proteins 
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only interact with the dimeric form.  The end result of this phosphorylation is the 
downregulation 14-3-3 activity [76, 77, 99, 100]. 
 In addition to the previously mentioned proapoptotic proteins that interact with 
14-3-3, numerous other target proteins have been identified, many that may directly or 
indirectly play a role in the cell survival/apoptosis balance.  These proteins include the 
MAP3K stress response proteins, Ask1 (or Map3k5), Mekk1, Mekk2, and Mekk3; 
mitogenic promoters, Raf (previously detailed) and Mek; nutrient signaling protein 
Ampk; and survival regulators Igf1r and Pi3 kinase [76].  
 In contrast to the number of 14-3-3 interactions that support cell survival, 14-3-3 
has also been found to bind to and stabilize E2f1, a proapoptotic transcription factor.  The 
end result is the expression of proapoptotic target genes p73, Apaf-1, and caspases.  
Overall however, current research supports a greater role for 14-3-3 in normally 
promoting regulation of proapoptotic proteins and supporting cell survival [76].   
 14-3-3 proteins have also been shown to play a key role in cell cycle regulation 
(Figure 5.4; Table 5.1) and are believed to have roles in cancer formation [101].   Cell 
cycle progression is regulated by interactions among the cyclin-dependent kinases 
(CDKs) and additional regulator subunits.  One important member of the CDK family is 
cell division cycle 2 (Cdc2; also known as Cdk1) whose activation is required for entry 
into mitosis.  Cdc2 is suppressed following DNA damage and during interphase by 
phosphorylation, but Cdc25c phosphatase dephosphorylates Cdc2 to allow cell cycle 
progression.  Cdc25c however can be regulated itself by phosphorylation by checkpoint 1 
kinase (Chk1) and subsequent binding to 14-3-3 proteins during interphase and at cell 
cycle checkpoints, which results in inhibition of mitotic entry [78, 102-104].   
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Interestingly, once Cdc2 is activated by Cdc25, it phosphorylates Cdc25 at Ser 214 in a 
positive feedback loop blocking potential inhibitory phosphorylation at Ser 216 which 
would lead to a mid-mitotic checkpoint [105]. 
  Chk1, the kinase that aids in the regulation of Cdc25, is also itself regulated by 
association with 14-3-3.  Phosphorylation of Chk1 in response to DNA damage activates 
it and causes it to associate with 14-3-3 proteins [78, 106, 107].   
 Another cell cycle protein regulated through interactions with 14-3-3 ζ is Mdxd, a 
p53 regulator.  Cellular DNA damage stimulates the phosphorylation of Mdxd leading to 
its binding to 14-3-3 proteins.  Mdxd complexed with 14-3-3 leads to the ubiquitinylation 
of Mdxd by Mdm2 and its subsequent degradation.   The reduction of Mdxd leads to the 
activation of p53 and cell cycle arrest or apoptosis [108]. 
 One CDK inhibitor, p27, regulates the cell cycle through its interactions with 
cyclin-CDK complexes within the nucleus.  p27 is regulated by its concentration and 
cellular localization and phosphorylation on one of numerous residues results in either its 
degradation or cytoplasmic localization.  Phosphorylation by Akt at Thr-157 allows p27 
to bind to 14-3-3 ζ which results in cell cycle progression [78, 109, 110]. 
 The last group of cell cycle regulators shown to interact specifically with 14-3-3 ζ 
belongs to the Forkhead family of transcription factors (Foxo) which aid in cell cycle 
arrest.  Phosphorylation of Foxo3a (also known as FKHRL1), Foxo1 (Fkhr), and Foxo4 
(Afx) (the three major mammalian Foxo members) by Akt leads to their association with 
14-3-3 ζ , cytoplasmic localization, and cell cycle progression [111-114].  
While much research interest has centered on the role of the 14-3-3 proteins in 
cell cycle regulation and apoptosis, recent proteomic studies have greatly enlarged the 
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scope of understanding of the role of these proteins within the cell.  In addition, while 
historical studies have not differentiated between the binding affinities of various 
isoforms, more recent research is beginning to shed more light on potential isoforms 
differences.  One recent research project by Meek et al. purified over 300 proteins 
(Appendix B) that were found to bind to 14-3-3ζ in HeLa cells during both interphase and 
mitosis.  While some target proteins were cell cycle dependent, many were cycle 
independent.   Roles of the target proteins within both phases included cell division, cell 
signaling (kinases, small GTPase related, misc.), nucleolar proteins, 
proteolysis/ubiquitination, stress or checkpoint response, apoptosis, nucleotide 
metabolism, chromatin structure/DNA binding, RNA binding, translation, cytoskeleton, 
metabolism, chaperones, nuclear transport, transcription, sugar binding, and vesicle 
trafficking/formation.  One interesting note was that Yhwaz was found to bind to Prdx1, 
the first gene of interest in this study, in a cell cycle independent manner [74].  The great 
diversity of target proteins and associated functions indicate a role for the 14-3-3 
proteins, especially 14-3-3ζ, in a wide range of cellular activities.   
 
Ywhaz Research Significance 
 While the exact function of Ywhaz within the cell is unclear, the diversity of its 
known interactions with over 300 other proteins signifies important roles in cell division 
and cell regulation.  In general, Ywhaz is believed to support cell growth proteins and 
repress proapoptotic genes [101].  This is supported by the research finding that increased 
Ywhaz levels increases a cell’s resistance to proapoptotic signaling.  The need for 
continued cell division is an established need for maintenance of a stem cell line and 
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therefore it is not difficult to understand the need to upregulate Ywhaz in stem cells.  
Continued cell division however is also a key characteristic of early developing embryos 
so it is not surprising that a greater fold difference of expression was not found.  While 
Tukey’s HSD statistical analysis of the real time data did not reveal statistical differences 
between the blastocyst and stem cell samples for Ywhaz, the alternative LSD analysis did 
find statistical differences between the C57BL/6 sample and blastocyst sample (data not 
shown) and therefore should be included for analysis in further research studies. 
 
Voltage-dependent Anion Channel 3 
In contrast to Prdx1 and Ywhaz, the blastocyst sample had the lowest level of 
expression for Vdacs3.  The fibroblast feeder cells had a 2.16 fold difference of 
expression, the 129SvEv stem cells had a 68.07 fold difference of expression, and the 
C57BL/6 stem cells had a 161.04 fold difference of expression.  When comparing the 
∆CT values, the blastocyst sample was statically different from both of the stem cell 
samples.  In addition, the fibroblast sample was also significantly different from either 
stem cell sample. 
 
Vdac3 Overview 
 The voltage-dependent anion channel (Vdac) family (also called mitochondrial 
porins) in mammals consists of three proteins, Vdac1, Vdac2, and Vdac3, which form 
pores within the outer mitochondrial membrane (OMM).  In addition to the majority of 
research focused on their role in mitochondria, further research has found Vdac within 
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other cellular compartments (Table 5.2) including the sarcoplasmic reticulum (SR), 
endoplasmic reticulum, endocytotoic vesicles, and the plasma membrane [115-117].  In 
addition, Vdac1 was co-purified in rats with the GABAA receptor complex obtained from 
neuronal plasma membranes [118].  
Mitochondria, once understood only as cellular energy producers, have been 
linked to a much broader role, including responsibilities controlling redox reactions, 
osmosis, pH, calcium levels, cell signaling, stress response, proliferation, intercellular 
communication, and apoptosis [116].  As the major OMM pore forming protein in 
addition to serving as a binding site for several cytosolic proteins, the Vdac proteins play 
important roles in these various functions[116, 119]. 
Vdac proteins have been found within all eukaryotic species however more 
complex organisms have been shown to have more isoforms (3) than the more simplistic 
species (1).  Within mice, the three isoforms are 65-70% identical and Vdac3, the 
isoforms of interest, is a 30 kDa protein coded by chromosome 8 [116, 119, 120].   Vdac3 
has also been shown to have an alternative splicing site in mice that adds a single 
methionine and is specifically expressed within the brain, heart, and skeletal muscle 
[121].  
The Vdac pore is generally formed from a single peptide consisting of one α-helix 
and several (13-19) amphipathic β-strands.  Together, it forms a transmembrane voltage-
gated pore (Figure 5.5) which serves to transport anions, cations, ATP, Ca2+, and other 
metabolites at low transmembrane potentials with reduced conductivity at high 
transmembrane potentials [115, 116, 122].  In mice, Vdac3 has also been shown to 
contain an additional leucine zipper motif in the portion of the peptide that is believed to 
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form the cytoplasmic loop [119, 123].  While most research has found the Vdac pore to 
be formed from a single peptide, recent research has also shown the ability of Vdac to 
join in dimers or tetramers within cellular membranes  [124, 125]. 
When cellular extracts of Vdac is reformed within planar lipid bilayers, the pore 
routinely fails to completely close, however numerous other proteins and inhibitors 
(Table 5.3) have been able to invoke closure or modify channel activity under 
experimental conditions, leading to the belief that Vdac has a complex regulation 
mechanism [115].   
The three Vdac isoforms have great structural homology and cellular differences 
between them have not been greatly defined, however they have been shown to display 
some functional differences.  In one experiment, each of the three murine isoforms was 
individually expressed in mutant yeast lacking the endogenous Vdac gene.  Both Vdac1 
and Vdac2 were able to complement the deficiency to restore normal growth potential, 
but Vdac3 was only able to partially complete the mutation [119].  Other researchers also 
expressed each of the isoforms individually in mutant yeast lacking Vdac and found that 
the expression of each isoforms resulted in varying degrees of mitochondrial membrane 
permeability.  In addition, while Vdac3 could be inserted into liposomes, it had difficulty 
inserting into planar membrane, especially in the presence of an ion gradient, and when 
inserted, did not respond like Vdac1 or Vdac2 to changes in the membrane potential 
[126]. 
In another experiment, knockout murine embryonic stem cell lines for each of the 
isoforms were generated and examined.  While there were no statistically significant 
differences in growth rates for the cell lines with single mutations, double mutant cell 
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lines could not be generated.  In addition, the singularly mutant cell lines all 
demonstrated a 30% decrease in oxygen consumption, and while Vdac1 -/- and Vdac2 -/- 
lines also showed a decrease in cytochrome c oxidase activity, Vdac3 -/- showed normal 
activity.  In Vdac1 -/- cell lines, an increase of citrate synthase was detected, indicating 
an increase in mitochondria, however in Vdac 2-/- and Vdac3 -/- lines, an increase in 
Vdac1 expression was detected by Western blot [127].  (Isoform specific antibodies were 
not available for Vdac2 or Vdac3 and therefore were not tested.)  So while any individual 
isoforms appears to be dispensable, at least two are required by the cell for survival and 
each of the three isoforms appear to have overlapping, but different mechanisms of 
operation.    
Subsequent research in the same laboratory generated mice deficient in Vdac3 
from heterozygous mice in normal Mendelian ratios, indicating no lethal effect in 
embryogenesis.  While the resulting mice appeared overall healthy, the males showed 
significant decreases in sperm motility (17% versus wild type 70%) and proved infertile.  
Further examination revealed 68% of Vdac3 knockout sperm have abnormal axonemes 
structure while tracheal epithelial had normal cilia, but fewer ciliated cells.  Mitochondria 
within testicular spermatids and skeletal muscles were found to be enlarged and 
abnormally shaped.  Respiratory chain activity was also decreased with skeletal 
mitochondria [128].  More recent research in bovine, localized Vdac2 and Vdac3 to the 
cytoskeletal outer dense fibers of the sperm flagellum [129]. 
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Vdac3 Cellular Implications 
 Research is still needed to fully define the physiological roles of the Vdac 
isoforms within the mitochondria and other cellular compartments.  Within muscle cells, 
the sarcoplasmic reticulum stores Ca2+ and aids in the regulation of muscle contractions.  
Control of the calcium levels within the SR involves numerous proteins that are 
themselves regulated by phosphorylation [115].  It has been proposed that Vdac functions 
within the SR to both transport the ATP required for phosphorylation and to allow the 
transfer of cations and anions in order to prevent osmotic and potential changes when 
Ca2+ levels fluctuate [130].   
 Within the cell membrane, Vdac has been proposed to function within a large 
multicomponent chloride channel such as the outwardly rectifying chloride channel 
(ORCC) complex with the ability to function based upon environmental changes and 
regulation as a maxi-, midi-, or a mini-chloride channel [117].  The cystic fibrosis 
transmembrane conductance regulator (CFTR) regulates ORCC by inducing cellular 
release of ATP [131].   
Additional research has also linked Vdac located within the cell membrane to 
ATP release and cell volume regulation of murine cells [132] as well as brain tissue 
volume regulation in bovine [133].  Research on superoxide anion localization with rat 
heart mitochondria has also suggested a role for Vdac in transporting the superoxide 
anion out of the mitochondria [134]. 
 The Vdac isoforms have also been linked to roles in apoptosis through several 
different proposed models.  In apoptosis, mitochondria play an important role in releasing 
apoptogenic proteins such as cytochrome c and apoptosis inducing factor (AIF) into the 
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cytoplasm as the outer mitochondrial membrane increases permeability in response to 
cellular signaling.  Vdac alone however, normally forms a pore too small for the 
transmission of proteins as large as cytochrome c [116].   
One model proposes that stimulated Vdac closure within the mitochondrial 
membrane prevents ATP-ADP exchange across the membrane which results in rupturing 
of the membrane, cytochrome c release, and apoptosis [135].  Other research however has 
found that cytochrome c can be released from the mitochondria without disturbing the 
OMM integrity therefore lending support to alternative models [136, 137]. 
In a second model, Vdac functions as part of the permeability transition pore 
(PTP) that in response to cellular pro-apoptotic signaling, increases its permeability.  The 
PTP crosses both mitochondrial membranes and includes Vdac in the OMM,  
cyclophilin-D in the mitochondrial matrix, and adenine nucleotide translocase (ANT) in 
the IMM  [116, 138, 139].  Additional research has specifically linked the blockage of the 
mitochondrial membrane permeability transition (MPT) which plays a role in necrosis 
and possibly apoptosis to Vdac regulation by the Bcl-2 family.  Bcl-2 and Bcl-x likely 
block MPT by inhibiting Vdac activity while Bax is proposed to interact with Vdac to 
cause cytochome c permeation [116, 140, 141].   
 The recent discovery of the variable existence of Vdac in dimers, trimers, and 
tetramers also suggests the possibility of oligomeric Vdac functioning in apoptosis to 
increase mitochondrial membrane permeability.  Cellular proapoptotic stimulation may 
induce oligomeric formation allowing for the formation of pores large enough to allow 
molecules like cytochrome c to pass without disrupting membrane integrity.  In fact, 
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purified Vdac reconstituted into liposomes was stimulated to form oligomeric structures 
when stimulated by cytochrome c [124]. 
 Interestingly, research utilizing several different cell and Vdac sources found that 
overexpression of Vdac induced apoptosis [116, 142, 143].  However, overexpression of 
hexokinase isoforms I (HK-I), known to reduce Vdac conductance, in cells with an 
overexpression of Vdac, were found to be resistant to the induction of apoptosis [142].   
Proposed mechanisms of apoptosis induction from increased levels of Vdac include an 
increase in OMM leakage followed by decreased cell viability as well as possible 
increase in Vdac oligomerization followed by release of apoptotic proteins [116]. 
 In contrast to normal cells which undergo apoptosis when Vdac is overexpressed, 
analysis of AH130, a malignant cell line, found all three Vdac isoforms (1-3) to be 
overexpressed when compared to normal liver cells [144].  Since previous research had 
shown more than 100 fold increased mitochondrial binding of hexokinase in tumor cells 
than in normal cells [145], the three isoforms were cloned and sequenced.  Their primary 
sequences were found to be identical to Vdacs expressed in normal liver cells, therefore 
suggesting that the binding difference was the result of transcript differences rather than 
structural differences [144].  While increased hexokinase activity in tumor cells has been 
tied to tumor cells increased need for energy and anabolic precursors [144, 145],  it has 
also been found that the binding of hexokinase to Vdac with the OMM induces channel 
closure and prevents PTP opening for cytochrome c release.  Glucose 6-phosphate, a 
hexokinase product and a regulator of hexokinase activity, was able to re-open both Vdac 
and PTP [146].  The deducing of the mechanisms behind the dual role of hexokinase in 
increasing glycolysis and decreasing mitochondrial permeability in cancer cells as well as 
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ways to target it for cancer therapy is the subject of much current cancer thought and 
research [147-149].  
 
Vdac3 Research Significance 
 While interest in Vdac has generated a great deal of research within the past two 
decades, its complex role within the cell, especially differentiating between isoforms, has 
yet to be fully defined.  Like Prdx1, previous microarray research has also found Vdac to 
be highly expressed in murine embryonic stem cells [69].  Of the three genes studied by 
real time PCR in this current research, Vdac3 showed the greatest fold difference 
between the blastocyst sample and the embryonic stem cell samples and there are several 
possible explanations for its increased expression.  Vdac could be playing an important 
role in cell volume regulation in the rapidly dividing cells.  Future research characterizing 
the cellular localization of Vdac between the blastocyst sample and the ESC samples 
could provide useful information for this model.   
Increased levels of Vdac within the cell could also simply provide a greater 
abundance of the various metabolites known to pass through its pore as energy needs of 
the cell increases in response to continual cell division.  Similar to cancer cells, 
embryonic stem cells have a great need both for increased energy and increased 
metabolic components to allow for continual cell division.  This common characteristic is 
reflected in the large fold difference of expression between both stem cell samples and 
the blastocyst sample.  While the precise mechanism by which Vdac increases a cell’s 
viability is still being investigated, it is believed to be significant that Vdac is upregulated 
in both cancer cells and embryonic stem cells, in contrast to other cell lines that were 
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found to undergo apoptosis when Vdac was overexpressed.  Future research examining 
hexokinase levels between the blastocyst sample and the ESC samples could provide 
useful information for comparing the Vdac mechanism between cancer cell lines and 
ESC samples and confirming if hexokinase also serves as a protective anti-apoptotic 
mechanism in ESC. 
 
General Discussion and Conclusion 
 While previous research characterized embryonic development or embryonic stem 
cells, the current work focused on characterizing the genomic changes in the 
development of murine embryonic stem cells from blastocyst stage embryos.   A review 
of research literature for the three genes identified through SSH and specifically studied 
through real time PCR, Prdx1, Ywhaz, and Vdac3, suggests important roles in promoting 
cell survival and continued cell division.  Alterations of expression levels of all three 
genes have been found in cancer lines which have similar characteristics of continued cell 
division without normal occurrence of differentiation.  In addition, all three genes have 
been suggested as direct or downstream targets of Oct4, an essential gene known for its 
role in maintaining stem cell pluripotency [2].  While further studies remain to fully 
understand the actions of each of these genes within the cell, especially in distinguishing 
isoforms differences for each gene, the overall focus on allowing continued stem cell 
growth is clear. 
 One matter that remains for consideration concerns the different rates of 
expression between the two different ESC lines.  The focus of the research was to 
identify key overall differences in the progression from blastocyst to ESC.  By comparing 
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multiple strains, strain specific differences could hopefully be eliminated.  It is possible 
that the difference observed are strain related or they could be normal fluctuations that 
occur through the progression of the cell cycle.  It is also possible that the variation could 
also be passage related.  The ESC samples were generously donated by Dr. 
Hochgeschwender from OMRF and at the time of original sample collection, it was noted 
that the 129SvEv sample was from passage 10 and the C57BL/6 sample was from 
passage 2.  It would be ideal to try to eliminate this variable in future research.  However, 
since the real time PCR analysis was designed to quantitatively confirm the results 
achieved through SSH, the overall statistically significant trend towards upregulation for 
Prdx1 and Vdac3 in ESC still provides valuable information on the differences between 
blastocyst stage embryos and embryonic stem cells. 
 Future research could take several directions.  Ideally, additional differentially 
expressed gene would be identified through SSH and quantified through real time PCR to 
provide a more complete profile of the genetic transition occurring during the formation 
of ESC.  In addition, the other 20 genes already identified in this study should also be 
analyzed through real time PCR within the same samples to look for additional 
statistically significant differences.  For the three genes analyzed in this work, additional 
research measuring their expression across timelines within embryos, as stem cells are 
developed from those same embryos, and as the stem cell colonies continue to replicate 
could provide useful information on their role over time within each sample.  The varying 
results found for Prdx1 between genomic and proteomic studies also encourage inclusion 
of proteomic analysis. 
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 While this current work identifies a small sample of the potential genes involved 
in the transition from blastocyst stage embryo to embryonic stem cell line, it offers a 
valuable first step in understanding the molecular alterations that occur during this 
essential time period.  Peroxiredoxin 1 and Voltage dependent anion channel 3 both 
demonstrated significant upregulation in the comparison between blastocyst stage 
embryos and ESC and function to enhance cell survival and continued cell reproduction.  
It is the author’s hope that future research will continue to expand our understanding of 
this transitional period in order to identify key markers of stem cell development in 
embryonic sources with potential applications in the development of future alternative 
sources. 
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Figure 5.1 Reduction of Hydrogen Peroxide by Peroxiredoxin.  [51] 
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Figure 5.2  14-3-3 Dimeric Structure.  The nine alpha helices are shown as cylinders 
and notated as αA – αI.  [77] 
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Figure 5.3 14-3-3 Apoptosis Regulation. 14-3-3 proteins, indicated by the copper 
colored dimeric loops, sequester proapoptotic proteins in the cytoplasm as a result of 
cellular survival signals.  JNK phosphorylation of 14-3-3 dimers at Ser 184 or the 
formation of 14-3-3 monomers by the phosphorylation at S58 by SDK/PKA in response 
to cellular damage or stress signals causes the release of these proapoptotic proteins and 
their subsequent migration to the mitochondria or nucleus.  [76] 
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Figure 5.4 Summary of 14-3-3 protein interactions during the cell cycle.  Taken from 
Hermeking and Benzinger [78]. 
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Table 5.1 Cell cycle regulators affected by 14-3-3 binding.  Adapted from Hermeking 
and Benzinger [78].   
 
Cell cycle 
phase  
Cell cycle 
regulator 
14-3-3 
isoform 
Phosphoryla-
tion site Kinase  
Effect of 
association Reference 
G1–S 
 
CDK2  σ n.d. 
 
n.d.  
 
Cytoplasmic 
sequestration  
[150] 
 CDK4  σ 
 
n.d. n.d.  
 
Cytoplasmic 
sequestration  
[150] 
 CDC25A  ε 
 
S178, T507  
 
CHK1 Cytoplasmic 
sequestration  
[151] 
 p27  ε, η, τ 
 
T198 AKT  
 
Cytoplasmic 
sequestration  
[110] 
 p27 ε, η, σ, τ 
 
T198 RSK  
 
Cytoplasmic 
sequestration  
[152] 
 p27  β, ε, γ, τ, ζ 
 
T157 AKT  
 
Cytoplasmic 
sequestration  
[109] 
 FOXO1 β, γ, η, τ, ζ 
 
T24, S256  
 
AKT  
 
Cytoplasmic 
sequestration  
[112, 113] 
 FOXO3a ζ T32, S253  
 
AKT  
 
Cytoplasmic 
sequestration  
[114] 
 FOXO4 ζ T28, S193  
 
AKT  
 
Cytoplasmic 
sequestration  
[111] 
 MIZ1 η, (γ,τ,σ) S428, T291  
 
AKT, n.d.  
 
Inhibition of 
DNA-binding  
[153] 
       
G2–M CDC2 σ n.d.  n.d.  
 
Cytoplasmic 
sequestration 
[150, 154] 
 CDC25B β, ε S309  
 
CHK1, p38  
 
Cytoplasmic 
sequestration  
[155-157] 
 CDC25B  σ S216  CHK1  
 
Unclear  [157] 
 CDC25C ε, γ, ζ S216  
 
CHK1, 
CHK2,  
c-TAK1  
Cytoplasmic 
sequestration  
[104, 158-
160] 
 WEE1  β, σ S642  
 
CHK1 Increase of 
kinase activity  
[161-163] 
 WEE1  τ S642  
 
AKT Cytoplasmic 
sequestration 
[164] 
 CHK1  β, ζ S345  
 
(ATR)  
 
Nuclear 
retention  
[106, 107] 
       
 p53 γ, ε, τ S378  
 
PKC Increase in 
DNA-binding  
[165, 166] 
 p53 σ n.d. n.d.  
 
Increase in 
DNA-binding 
[167] 
 MDMX β, γ, ε, η, τ, ζ S367 n.d. Degradation [108] 
 
n.d. – not determined 
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Table 5.2  Cellular Localization of Vdac.   Adapted from Reyman, et. al [117] and 
Shoshan-Barmatz and Israelson [115].  
Cell Component Cell Source Vdac Isoform (if known) Reference 
Cane toad, Bufo marinus  [168] Sarcoplasmic 
reticulum Rabbit skeletal muscle Vdac1 + Vdac? [130, 169] 
Endoplasmic 
reticulum Rat cerebellum  [125] 
Bovine astrocytes Vdac1 [133] 
Human lymphocytes Vdac1 [117, 170] 
Rat neurons Vdac1 [118] 
Synaptosomes of 
Torpedo Electric Organ, 
Torpedo marmorata and 
Torpedo oscellata 
Multiple versions – 
closest matches to 
Vdac1 and Vdac3 
[171] 
Caveolae and caveolae 
like domains from rat 
heart, bovine brain, dog 
lung, and human lymph-
ocytes, megakaryocytes, 
promyelocytes, 
monocytes 
Vdac1 [172] 
Plasma membrane 
Mouse lung caveolae Vdac1 per [172] [173] 
Endocytotic 
vesicles Rat renal cortex Vdac1 [174] 
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Figure 5.5  Model of VDAC in the Mitochondrial Membrane.  [122] 
protein binding site?  
Cytosol 
Intermembrane space 
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Table 5.3  Modifiers of Vdac channel activity.  Adapted from Shoshan-Barmatz and 
Israelson [115]. 
 
Molecule Reference 
Ruthenium red (RuR) [115, 138, 175] 
Ruthenium amine binuclear complex (Ru360) [115, 138, 176] 
Dicyclohexylcarbodiimide (DCCD) [130, 169] 
4,4’-diisothiocyanostilbene-2,2’-disulfide acid (DIDS) [115, 130] 
Soluble protein [177, 178] 
Hexokinase (HK-1) [115, 146] 
NADH [179] 
LaCl3 [115, 175, 176] 
Glutamate [115, 138, 176, 180, 181] 
Polyamines [182] 
Polyanions [183] 
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Appendix A 
 
Alternative Gene Names 
Prdx1 Prdx1 Peroxiredoxin 1 
 Prx1 Peroxiredoxin 1 [184] 
 MSP23 Macrophage 23-kDa stress protein (mouse) [185, 186] 
 OSF-3 Osteoblast specific factor 3 (mouse) [186, 187] 
 PAG Proliferation associated gene (human) [56, 186] 
 HBP23 Heme-binding protein 23 kDa (rat) [186, 188] 
 NKEF-A/NKEFA Natural killer enhancing factor A [184, 189] 
   
Ywhaz Ywhaz 
Tyrosine 3-monooxygenase/tryptophan -  
5-monooxygenase activation protein, zeta 
peptide 
 14-3-3 ζ 
Named based on its isolation pattern via 
(DEAE)-cellulose chromatography and 
starch-gel electrophoresis [71] 
   
Vdac3  Mitochondrial porins [119] 
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Known Ywhaz Target Proteins [74] 
 
 140 
 141 
 142 
 143 
 144 
 
 145 
 146 
 147 
 
 148 
   
VITA 
 
Sarah Elizabeth Myer 
 
Candidate for the Degree of 
 
Doctor of Philosophy  
 
 
Thesis:    DIFFERENTIAL GENE EXPRESSION OF MURINE BLASTOCYST 
STAGE EMBRYOS AND MURINE EMBRYONIC STEM CELLS 
 
 
 
Major Field:  Biomedical Sciences 
 
Biographical: 
 
Personal Data:  Born in North Carolina, the daughter of G. Edward Lowder and 
Pamela A. Lowder.  Married to Brian J. Myer.  Mother of two daughters, 
Hannah E. Myer and Maggie S. Myer. 
 
Education:  Graduated from North Carolina School of Science and 
Mathematics, Durham, NC, in 1990; received Bachelor of Arts in 
Biology from Oral Roberts University, Tulsa, Oklahoma, in 1994; 
received Masters in Education from Oral Roberts University, Tulsa, 
Oklahoma, in 1995.  Completed the requirements for the Doctor of 
Philosophy degree at Oklahoma State University Center for Health 
Sciences, Tulsa, Oklahoma in December 2007. 
 
Experience:  Instructor of Biology at Oral Roberts University, 1999-present.  
Instructor of 7th grade Life Science at Sapulpa Middle School, 
Oklahoma, 1995-1999. 
 
Professional Memberships:   
Oklahoma Academy of Science
   
Name: Sarah E. Myer                              Date of Degree: December, 2007 
 
Institution: Oklahoma State University              Location: Tulsa, Oklahoma 
 
Title of Study: DIFFERENTIAL GENE EXPRESSION OF MURINE BLASTOCYST 
STAGE EMBRYOS AND MURINE EMBRYONIC STEM CELLS 
 
Pages in Study: 148                 Candidate for the Degree of Doctor of Philosophy 
Major Field: Biomedical Sciences 
 
Scope and Method of Study: Embryonic stem cells (ESC), derived from cultured  
blastocyst embryos, have the potential to provide insight into developmental and 
medical issues.  The cellular transition, however, from blastocyst to ESC has not 
been well characterized.  The purpose of this study was to identify transcriptional 
differences between blastocysts and ESC through use of suppression subtraction 
hybridization (SSH) in murine CD1 blastocyst and 129SvEv ESC.  Comparisons 
between the following groups: blastocyst - blastocyst, trophectoderm - blastocyst, 
blastocyst - ESC, and ESC – fibroblast feeder cell, resulted in the cloning, 
sequencing, and identification of uniquely expressed sequences. The second 
objective was to compare expression levels of three selected transcripts through 
real time PCR in blastocysts, 129SvEv ESC, C57BL/6 ESC, and fibroblast feeder 
cells. 
 
Findings and Conclusions:  Using SSH, 33 unique clones were identified and 10 had   
strong ribosomal homologies while 23 had either gene specific homologies or else 
were unknown.  Prdx1, Ywahz, and Vdacs3 were analyzed through real time 
PCR.  For Prdx1, fibroblast feeder cells had the lowest expression level, 
blastocysts had a 4.81 fold increase, 129SvEv ESC had a 7.51 fold increase, and 
the C57BL/6 ESC showed a 27.28 fold increase.  Expression levels were 
significantly different between the blastocyst and C57BL/6 samples as well as the 
fibroblast feeder cells and both ESC samples based on ∆CT statistical analysis.  
For Ywhaz, the fibroblast feeder sample showed the lowest expression level, 
blastocysts had a 7.65 fold increase, 129SvEv ESC showed a 6.49 fold increase, 
and C57BL/6 ESC showed a 16.56 fold difference.  The two ESC values were 
significantly different as was the fibroblast feeder cell value from all other 
samples.  For Vdacs3, the blastocyst sample had the lowest level of expression, 
fibroblast feeder cells had a 2.16 fold difference, 129SvEv ESC had a 68.07 fold 
difference, and C57BL/6 ESC had a 161.04 fold difference.  Statistically, the 
blastocyst sample was different from both of the ESC samples and the fibroblast 
sample from either ESC sample.  Prdx1 and Vdacs3 both demonstrated significant 
upregulation in comparison between blastocyst stage embryos and ESC and 
function to enhance cell survival and continued cell reproduction. 
 
ADVISER’S APPROVAL:        Dr. Lee F. Rickords 
